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Amyotrophic lateral sclerosis (ALS) is a fatal disease of the nervous system. The majority 
of  ALS  cases  are  have  no  attributable  genetic  link,  however  approximately  10%  are 
familial and 20 % of these result from mutations in the SOD1 gene. How SOD1 mutation 
manifests as the ALS phenotype is not clear however the enzyme does gain an aggregative 
property characterised by SOD1 inclusions in the brain and spinal cord. Drug treatment for 
sporadic  and  familial  ALS is  currently limited  to  palliatives  and  there  is  currently no 
specific treatment for SOD1 mediated ALS. In order to find molecules that may be of use 
in the development of SOD1 therapeutics a crystallographic screening pipeline was set up 
to assess binding of small molecules to both wild-type and SOD1 mutants.
Using in silico studies and previous crystallographic work as a starting point, this method 
revealed several low molecular weight compounds (Mr 183 – 310 gMol-1) that have SOD1 
binding  activity.  These  molecules  belong  to  three  distinct  classes:  catecholamine, 
quinazoline and fluorouridine and occupy two distinct binding sites on the surface of the 
SOD1 β-barrel in an area known to be important in disease pathogenesis.
The incorporation of copper into biological macromolecules such as SOD1 is essential for 
the viability of most organisms. However, copper is toxic and therefore the intracellular 
free copper  concentration is  kept  to  an absolute  minimum. The Copper  Chaperone for 
SOD1 (CCS) is the major pathway for SOD1 copper loading and transfer of an intrasubunit 
disulphide bond known to stabilise SOD1.
Using small angle X-ray scattering combined with online size exclusion chromatography 
high quality data were acquired for both homodimeric hCCS and the functionally critical 
hCCS-SOD1 heterodimer.  SAXS measurements were made of the hCCS complex with 
wild-type SOD1 and the disease relevant L38V and I113T SOD1 mutants. A rigid body 
modelling approach enabled exploration of the conformational dynamics of each species. 
Homodimeric  hCCS  is  found  to  adopt  positions  that  would  facilitate  initial  copper 
acquisition and transfer from domain I to domain III.  This domain III is also found in 
positions that would allow disulphide and copper transfer to SOD1 in the heterodimeric 
complex. The hCCS-I113T SOD1 complex has characteristics which are convergent with a 
view of ALS initiated by improperly matured SOD1.
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Chapter I 
ALS, SOD1 and drug development
1.1 Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is an idiopathic neuropathy of humans characterised 
by death of the upper and lower motor neurons leading to muscle atrophy, paralysis and 
death 1. ALS has an incidence of 3.0 and 2.4 per 100,000 person years for men and women 
respectively in Europe 2. This is reflected in other population registries where information 
is  available 3 and  equates  to  approximately  a  1  in  500  probability  of  an  individual 
developing ALS over their life span. These figures can be compared with those pertaining 
to multiple sclerosis 4.2 per 100,000, Parkinson's disease 14 per 100,00 4 and Alzheimer's 
disease 750 per 100,000 5.
Symptoms that give rise to initial presentation are varied but can be divided roughly into 
bulbar onset and limb onset. Bulbar onset effects 42% 6 of patients and is characterised by 
dysarthria,  dysphagia or sialorrhoea  7. Limb onset ALS is seen in 58% 6 of cases and is 
associated with muscle weakness or atrophy, fasciculations and cramps 7. A small minority 
of patients present initially with respiratory weakness not associated with bulbar or limb 
symptoms  8. As the disease progresses fatigue and reduced activity become  common  9. 
Malnutrition and sialorrhoea,  arising from an inability to swallow, together with reduced 
respiratory function and uncontrolled expression of emotion  10 are observed in the later 
stages. Death usually arises from respiratory failure often associated with pneumonia 11.
ALS is inexorably progressive with 70 - 80% of patients dying within 5 years of the onset 
of symptoms 6. Although there is a slight preponderance of ALS in men rather than women 
its occurrence is largely unpredictable. Approximately 90% of ALS cases are sporadic and 
have no clearly attributable cause 12.
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1.2 Familial Amyotrophic Lateral Sclerosis and associated proteins
The remaining 10% of ALS cases have a genetic link with one of several susceptibility loci 
that have varying degrees of genetic penetrance and resultant disease severity 13. A small 
number of familial amyotrophic lateral sclerosis (fALS) cases have been observed to show 
an autosomal recessive inheritance pattern 14,15 but the majority are autosomal dominant 16-
18.
While 13 ALS loci have been discovered only 6 have a substantive pathological connection 
with known proteins. Alsin is a GTPase regulator encoded by the ALS2 gene at position 
q33 on chomosome 2 and is responsible for an early onset, recessive form of ALS resulting 
from C-terminal truncation  14,19 . The SEXT gene at 9q34 encodes the senataxin protein, 
several mutations in which have been found to determine an early onset form of ALS with 
slow disease progression  16. Mutations in the OPTN gene at locus 10p15 which encodes 
optineurin, previously implicated in open angle glaucoma, have been associated with an 
autosomal dominant ALS characterised by late onset 20. Similarly, two point mutations in 
the  VAPB  locus  at  20q13  have  been  discovered  to  be  responsible  for  an  autosomal 
dominant atypical form of ALS associated with adult onset spinal muscular atrophy 21,22.
TDP-43 (Tar  DNA Binding Protein-43)  and FUS (Fused In Sarcoma)  are  nucleic  acid 
binding  proteins  coded  for  at  loci  at  chromosomal  locations  1p36  23 and  16p11  24 
respectively.  Both  of  these  proteins  were  first  identified  through  implications  in  other 
diseases. The FUS locus was found to undergo a translocation in liposarcoma tumours that 
created a  chimeric  protein together  with the transcription regulator  CHOP  24.  Ou et  al 
discovered that TDP-43 binds to and represses transcription from the HIV long terminal 
repeat  sequence  TAR  25.  Autozygosity  mapping  subsequently  uncovered  a  direct 
connection between mutation of these two protein and fALS 18,26. Interestingly, TDP-43 had 
previously been observed to form a major component of intracellular inclusions found in 
the  brain  and  spinal  cord  of  patients  with  sporadic  ALS  and  frontotemporal  lobar 
degeneration 27. Mutations in the TDP-43 sequence were also found in cases of sALS 18.
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1.3 SOD1 genetics
Approximately 20% of familial ALS cases are associated with mutations in the superoxide 
dismutase-1  (SOD1)  encoding  gene  found  on  chromosome  21  at  location  q22.1  17. 
Mutation in the SOD1 gene therefore accounts for 1 – 2% of all ALS cases which is the 
highest proportion of any of the known causative genetic elements.
To  date  there  are  159  documented  ALS  causing  SOD1  mutations  28.  An  affected 
individual's life expectancy after initial onset of symptoms is defined, to a large extent, by 
the mutation 29,30. These mutations are diverse in nature and include amino acid deletion 31 
and insertion 32, deletion of base pairs in the 3' untranslated region 33, premature truncation 
34 and amino acid  substitution  17, the latter of which is by far the most common. These 
mutations are for the most part dominantly inherited 17 with individuals heterozygous for 
the pathogenic mutation. However, homozygous sufferers have been observed indicating a 
possible recessive inheritance pattern  35,36 which, surprisingly, in one case was associated 
with a juvenile onset and rapid disease progression 35.
1.4 Superoxide and SOD1 catalytic function
The existence of the superoxide radical (O2-) was first postulated by Linus Pauling in 1931 
as an aside to  his work on the quantum mechanics of the chemical bond 37. It is produced 
in  vivo as  a  result  of  the  aberrant  univalent  reduction  of  dioxygen  by leaky electron 
transport in mitochondrial oxidative phosphorylation 38. Superoxide is easily converted into 
the highly toxic hydroxyl radical (•OH) and peroxynitrite (ONOO-). Up to 2% of electrons 
passing through the electron transport chain are lost to the environment so reactive oxygen 
species,  including superoxide,  would quickly render  the cell  dysfunctional  and lead  to 
necrosis  without  a  neutralisation  strategy.  The  superoxide  dismutase  class  of  enzymes 
catalyse  the  dismutation  of  superoxide  to  dioxygen  and hydrogen  peroxide  39 and  are 
employed to deal with this toxic threat.
Human SOD1 (EC 1.15.1.1) when fully mature contains one copper and one zinc ion per 
monomer 40. The redox potential of copper in the SOD1 active site enables it to efficiently 
catalyse the dismutation of the superoxide radical to dioxygen and hydrogen peroxide by 
cycling back and forth between the Cu(I) and Cu(II) oxidation states according to the two 
16
step reaction 39:
O2- + Cu2+ZnSOD → O2 + Cu1+ZnSOD
O2- + Cu1+ZnSOD +2H+ → H2O2 + Cu2+ZnSOD
This  reaction is  very efficient  and proceeds  at  almost  the  diffusional  limit  with a  rate 
constant of 109 M-1 s-1 41 as opposed to spontaneous dismutation which operates at 105 M-1 
s-1 42.
SOD1 is a structurally conserved protein present in widely divergent species  43,44 and is 
constitutively  expressed  in  almost  all  human  cells  45 underscoring  the  biological 
importance of this enzyme. It is found predominantly in the cytosol  46 and mitochondrial 
intermembrane  spaces  of  eukaryotic  cells  47 but  also  in  the  nucleus,  peroxisomes  and 
lysosomes 48.
1.5 SOD1 structure
Human SOD1 is a 32 kDa homodimer composed of two non-covalently associated 153 
amino  acid  subunits.  The  first  structure  of  SOD1  was  that  of  the  bovine  enzyme 
determined at 2.0 Å resolution in 1982 49. The wild-type human protein was described at 
2.5 Å resolution in 1992 with a focus on designing thermally stable recombinant SOD1 
proteins for therapeutic use combating free radical mediated disease 50. This was followed 
in 2006 by a 1.07 Å atomic resolution structure of wild-type native human SOD1 51.
These studies indicated each SOD1 monomer is composed of an eight strand anti-parallel 
Greek key β-barrel  connected by seven loops of  varying length (Figure 1.1).  Loop IV 
(residues  49  -  83)  is  the  largest  and  houses  Asp83,  His63,  His71  and  His80  which 
coordinate zinc in a tetrahedral conformation (Figure 1.2). This loop, termed the zinc loop, 
extends past the metal binding sites and contains a short 1½ turn α-helix (56 – 61) that is 
anchored to the β-barrel by an intrasubunit disulphide bond between Cys57 and Cys146. 
Loop VII (120 – 143), termed the electrostatic loop, also contains a 1½ turn α-helix and at  
its N-terminus His120 coordinates copper along with His46 and His48 of strand 4 of the β-
barrel (Figure 1.2).
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Figure 1.1. The structure of human SOD1. The SOD1 β-barrel is highlighted in red. Loops are highlighted 
purple except loop IV and VII, the zinc and the electrostatic loops which are highlighted green and cyan 
respectively. The copper and zinc sites are shown withblue and grey spheres respectively. PDB ID: 2C9V 51.
When the copper ion is oxidised His63 acts as a bidentate bridging ligand between the two 
metal  ions  and copper  is  coordinated  in  an  irregular  tetrahedral  fashion.  On reduction 
copper moves 1.0 Å away from His63 and is coordinated only by the imidazole group 
nitrogens of His46, His48, and His120 in a planar triangular conformation (Figure 1.2).
Figure 1.2. Detail of the SOD1 copper and zinc binding sites. Copper coordinating histidine residues are  
shown green with the bridging histidine purple. Zinc coordinating residues are shown in orange. The change 
in the position of the copper ion when in the reduced (left) and oxidised (right) forms can be observed. Co-
ordination between copper and nitrogens is marked with a black dashed line as is co-ordination by a single 
water molecule in the Cu(II) state.
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The N and C termini of the SOD1 polypeptide form short protrusions from the β-barrel and 
together with sections of loops IV and VI comprise the dimer interface.  This region is 
stabilised largely by hydrophobic interactions between the dimer counterparts.
1.6 SOD1 fALS disease pathogenesis
fALS associated SOD1 mutations are located throughout the full length of the 153 amino 
acid SOD1 primary sequence including zinc 52,53 and copper 54,55 site substitutions (Figure 
1.3).
Figure 1.3. Distribution of fALS associated mutations throughout the SOD1 open reading frame. Mutations 
found in loop regions are coloured purple and mutations found in the β-barrel are coloured red. The height of 
each bar represents the number of novel SOD1 mutations found at that particular site.
Indeed,  81  codons  (53%)  have  one  or  more  documented  fALS  mutations.  A close 
inspection of their position indicates a 20% increased probability that a residue will have 
one or more mutations inside the β-barrel  than in a loop (0.46 and 0.66 respectively). 
However strand 3 of the β-barrel (amino acids 30 - 36) is suspiciously free of mutations 
and is the longest unmutated region. On the other hand there are obvious hotspots not only 
in the β-barrel but in loops VI and VII, the electrostatic loop.
While  each  mutation  carries  an  increased  probability  of  the  individual  following  a 
particular disease course there  is no discernible correlation between the biochemical and 
structural characteristics of mutant SOD1 and patient phenotype 30,56. For example, mutant 
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SOD1 proteins have been observed to have dismutase activities varying from approaching 
nil up to 150% of the wild-type protein. This does not correlate with disease characteristics 
such as age of onset and life span after onset of symptoms  57-59. Therefore, disruption of 
dismutase activity cannot be the root cause of SOD1 associated ALS. If human SOD1 does 
not have an unknown function, distinct from its dismutase activity, that is deleteriously 
affected by these mutations it must gain a characteristic that it does not posses in its wild-
type form.
This notion is supported by a number of observations of transgenic mice. Those expressing 
fALS-associated human SOD1 mutants develop ALS-like symptoms in early adulthood 60,61
and these symptoms result  irrespective of the presence,  absence or expression level of 
wild-type SOD1  61.  Those expressing or over-expressing only human wild-type protein 
display no ALS-like symptoms 62,63 as do those completely deficient in the enzyme 64. 
Large SOD1 filled aggregates are observed in the spinal cord neurons of fALS effected 
individuals  and  fALS associated  SOD1 mutant  transgenic  mice  65-68.  These  aggregates 
interfere with axonal transport  69,70, cause aberrant apoptosis  71, damage the mitochondria 
72 and sequester the proteasome 73. The SOD1 toxic gain of function could be the ability to 
aggregate  however  the  mechanism  which  facilitates  this  aggregation  is  not  currently 
known or the reason it specifically effects motor neurons.
At  first  glance  SOD1 aggregation  appears  counter-intuitive  given  that  wild-type  fully 
metallated SOD1 remains correctly folded at temperatures approaching boiling point  74. 
However,  introduction of fALS associated SOD1 mutations was found to decrease the 
thermal stability as determined by differential scanning calorimetry  74. Similarly,  partial 
metallation of wild-type and mutant SOD1 proteins was also found to decrease thermal 
stability  74 with  loss  of  the  zinc  ion  from  wild-type  SOD1  substantially  promoting 
monomerisation  75 and  self  organisation  into  amyloid-like  structures  76,77 and  soluble 
aggregates 78,79.
Each SOD1 monomer contains one intramolecular disulphide bond between cysteines 57 
and 146 49. This bond is transferred from CCS (Copper Chaperone for SOD1) 80 during the 
copper loading process 81 or by a CCS-independent pathway 82. In fALS associated SOD1 
mutant proteins this bond is susceptible to reduction by glutathione at near physiological 
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levels  83.  Disulphide  reduction  was  observed  to  promote  SOD1  monomerisation  83 
particularly when the protein was partially zinc metallated  75. SOD1 monomerisation has 
been shown to precede aggregation 84,85 and introduction of a inter-subunit disulphide bond 
or  a  chemical  crosslink  between  adjacent  Cys111  residues  was  observed  stabilise  the 
protein and prevent polymerisation in vitro 86,87.
Thus destabilisation of the SOD1 dimer resulting from demetallation, disulphide reduction 
or a combination of both, appears to be a central characteristic of fALS associated mutants. 
This is corroborated by structural and computational molecular dynamics data that indicate 
a change in the nature of the dimer interface 88,89, increased dimer instability 85 and a loss of 
structural integrity in the zinc binding and electrostatic loop regions  90 on reduction or 
metal removal.
1.7 Available SOD1 fALS therapeutics and review of clinical trials in progress
The relatively low incidence of ALS classifies it as an orphan disease and consequently it 
has attracted little attention in terms of therapeutics  development from traditional  drug 
development agencies. Currently, Riluzole is the only approved drug for the treatment of 
ALS. It is known to increase life expectancy for an ALS sufferer by two months on average 
91. There are currently no available drugs specifically targeted to fALS or SOD1 mediated 
fALS.
Clinical and pre-clinical trials of SOD1 mediated fALS therapeutics have met with almost 
complete  failure,  however  some  recent  studies  are  worthy  of  note.  Arimoclomol  is 
currently undergoing phase II/III clinical trials 92. It is a co-inducer of heat shock proteins 
that enables the clearing of SOD1 aggregates by over-expression of protein chaperones and 
has been observed to prolong life expectancy in fALS mouse models by 22% when used in 
pre and early symptomatic individuals 93,94. However, when this drug was tested against late 
stage ALS mouse models, that exhibit  a greater degree of similarity to human patients 
initially presenting with ALS, it did not have any life prolonging effect 95.
A second therapeutic  approach  currently in  development  silences  gene  expression  and 
reduces the target protein concentration as old protein is degraded. This could practically 
be  achieved  by  nucleic  acid  hybridisation  96 or  chemical  inhibition.  SOD1  antisense 
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oligonucleotides  able  to  bind  nascent  SOD1  mRNA,  prevent  translation  and  increase 
survival time in rat G93A models after direct infusion into the ventricular system have 
been  documented  97.  Phase  I  clinical  trials  are  ongoing  for  this  therapy  but  while 
efficacious in animal models, this delivery method has obvious penalties for future patient 
comfort  and  care.  Similarly,  antisense  expressing  viral  systems  have  successfully 
transduced the CNS although their ability to retard disease progression is disputed 98,99.
Pyrimethamine, is a common drug used for the treatment of protozoal infections such as 
malaria and toxoplasmosis. It is reported to reduce SOD1 levels in G93A SOD1 mouse 100. 
In an initial 18 week, seven person clincial trial, this compound was observed to reduce 
blood  lymphocyte  SOD1  levels  by  30  –  60%  for  non-A4V  patients  100.  Conversely, 
pyrimethamine  was  not  observed  to  reduce  SOD1  expression  in  wild-type  mice  nor 
abrogate SOD1 synthesis in cell models 101 however this compound is currently undergoing 
phase I/II clinical trials.
The lack of efficacious fALS targeted therapeutics and the inherent problems associated 
with those strategies currently in the drug development pipeline provide a clear need for a 
drug discovery program targeted to SOD1.
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Chapter II
Drug discovery and crystallographic theory
2.1 Fragment based rational drug design
A traditional approach to drug development takes a defined biological target and screens 
millions of drug-like compounds for interactions using a minaturisable assay 102. While this 
methodology has been valuable in generating many of the therapeutics discovered in the 
20th century  it  is  inherently  limited  by  the  inverse  relationship  between  molecular 
complexity and lead discovery 103, and the low success ratio of lead optimisation 104. The 
large infrastructure investment needed for the successful completion of an initial screen, 
lead optimisation and arrival at a potential drug-like compound, even before clinical or 
toxicity trials begin, is prohibitive for all but the largest pharmaceutical companies. This 
effectively stalls drug development for diseases where there are low numbers of affected 
individuals or the end market is perceived to be too small to compensate for initial outlay 
105.
An alternative  approach screens  low molecular  weight  compounds  for  relatively weak 
binding to the target  106, which may not have been identified by a  in vitro assay, using a 
structure  based  technique  such  as  NMR  or  X-ray  crystallography  107.  These  small 
molecules  are  then  grown or  linked to  produce  larger  molecules  that  have  strong site 
specific binding 108 characterised by increased ligand efficiency 109. Throughout this process 
it is possible to engineer in Lipinsky 'Rule of 5'  110 compliance including hydrophilicity, 
low number of rotatable binds, low molecular weight (<500 Da), 5 or lower hydrogen bond 
donors or acceptors and other ADMET properties which will facilitate activity.
2.2 Crystallographic fragment-based drug discovery
The relative ease with which crystallisation and single crystal X-ray diffraction structure 
determination proceeds means crystallography is an ideal tool to feed information into the 
drug development  pipeline  throughout  its  course.  Its  use  in  initial  ligand screening  107 
enables the site of interaction to be determined unambiguously at the outset and directs 
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how chemical space should be probed during optimisation 111.
2.3 Crystallisation, compound soaking and data collection
A prerequisite for crystallographic protein structure determination is diffracting crystals. 
Crystallisation is the ordered precipitation of solute from a solution by nucleation followed 
by growth.  Throughout  this  work  SOD1 was  crystallised  by the  hanging drop vapour 
diffusion method (Figure 2.1A). Protein solution at a sufficiently high concentration was 
mixed 1:1 with the a precipitant solution and suspended over a reservoir of the precipitant 
solution. Initially the concentration of precipitant, [ppt], is given by
[ ppt reservoir]=2 [ ppt drop]
As water evaporates from the drop and condenses in the reservoir solution, this becomes
[ ppt reservoir]=[ ppt drop]
with a concomitant doubling of the protein concentration in the drop. This concentration 
shift pushes the drop from the unsaturated phase to the supersaturated phase (Figure 2.1B). 
The degree of supersaturation is the key-point in crystallisation experiment and can be 
affected by temperature, pH, protein concentration and precipitant concentration. Very high 
supersaturation  will  promote  disordered  expulsion  of  protein  from solution  leading  to 
amorphous precipation however if supersaturation cannot be achieved crystal nucleation 
will  not  take  place.  Nucleation  is  often  a  very  slow  process  but  its  necessity  can 
circumvented by addition of pre-existing seed crystals. The SOD1 crystals  used in the 
following  chapter  were  grown  from  seeds  originally  acquired  from  apo-H48Q  SOD1 
crystallisation and were transferred into the drop after equilibration.
Protein crystal  production for a ligand screening program is  complicated by a need to 
produce  crystals  which  are  resistant  to  the  solvents  commonly  used  in  soaking 
experiments,  such  as  dimethyl  sulfoxide  (DMSO)  or  dimethylformamide  (DMF).  The 
crystal must also have sufficiently large solvent pores to allow movement of the small 
molecules through the crystal lattice. These two attributes can be mutually exclusive with 
less dense crystal forms more liable to dissolve in organic solvents.
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Figure  2.1  (A)  Hanging  drop  vapour  diffusion.  (B)  Phase  diagram  of  protein  crystallisation  driven  by 
precipitant concentration.
Crystallographic data collection often takes place with the crystal in a stream of nitrogen 
gas at 100 K. This reduces the effects of radiation damage and means a single crystal is 
sufficient to collect all the data necessary for structure determination. While this reduces 
the demand for protein and ligand it is essential that the ligand be included in any aqueous 
cryoprotectant solutions in order that bound ligand is not dispersed during cryoprotection.
The  data  presented  in  the  following  chapter  were  collected  at  two  crystallographic 
beamlines:  Proxima  1 at  SOLEIL,  Paris,  France  and IO3 at  DIAMOND, Oxfordshire, 
England.  Details  of  data  collection  and  processing  can  be  found in  the  Materials  and 
Methods chapter.
2.4 Crystallographic theory
The minutiae of crystallographic theory are available in numerous canonical texts and it is 
not the  purpose of this work to review available information however, what follows is a 
brief description of that which is necessary to understand the work presented in chapter III.
The distribution of electrons (ρ) at a point (x, y, z) within a unit cell (with volume V) of a 
crystal can be described as the Fourier sum of its structure factors (Fhkl).
ρ(x , y , z )= 1
V ∑h ∑k ∑l
F hkl e
−2πi (hk+ky+lz)
25
2.5 Data reduction, scaling & merging
The first stage in the process of creating a model of a biomolecule by X-ray diffraction 
crystallography is  data  reduction.  That  is,  indexing of reflections to  correct  h,  k and  l 
values, unit  cell  parameter refinement and assessment of the intensity of reflections by 
background subtracted integration. The outcome of this process is a data set consisting of 
the Miller indices of each reflection (hkl), its intensity (Ihkl) and standard uncertainty (σIhkl). 
Throughout this work data reduction was performed with iMOSFLM 112 or HKL2000 113.
The intensity of each reflection can be affected by the intensity of the incident beam and 
variability  in  the  beam's  path  length  through  the  crystal  as  it  is  moved  into  different 
orientations. It cannot be assumed therefore, that the intensities measured directly from the 
diffraction image are consistent across the whole data set. This problem is eliminated by 
observing reflections with known index across more than one frame and scaling the dataset 
so that identical reflections have identical intensity throughout. This task was performed 
here using the programs SCALA 114 or HKL2000.
2.6 Isomorphous phasing
As stated previously, the electron density within a crystal unit cell can be expressed as the 
equation in Section 2.4 where the structure factor amplitudes and phases are implicit in the 
term Fhkl. This equation can be reformulated as
ρ(x , y , z )= 1
V ∑h ∑k ∑l ∣
F hkl∣e
−2π i (hk +ky+lz−α ' hkl )
which gives  electron density at  coordinate  (x,  y,  z)  of  the real  lattice as a  function of 
measured  structure  factor  amplitudes  │Fhkl│ and  phases  (α'hkl).   The  structure  factor 
amplitude is proportional to the square root of its intensity (Ihkl1/2) which can be directly 
measured  during  data  collection  however  the  phase  of  a  diffracted  ray arriving  at  the 
detector during an experiment cannot be directly measured. This phase information must 
be calculated for each reflection in order to derive a model of electron density from a series 
of diffraction images.
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The  phase  problem  is  a  major  hurdle  when  the  structure  of  a  new  protein  is  being 
experimentally  determined.  It  is  solved  most  frequently  by  isomorphous  replacement, 
anomalous  diffraction  or  molecular  replacement  methods.  However,  a  protein  crystal 
soaked in a putative ligand is unlikely to deviate hugely from the structure of the native 
crystal. A crystallographic approach to fragment based drug discovery necessitates that the 
structure of the target protein has already been solved. If this is the case the structure of the 
ligand-protein  complex  can  be  solved  using  phase  information  taken  from  the  native 
protein  structure  by  isomorphous  molecular  replacement  in  conjunction  with 
experimentally measured intensities from the complex.
In the following chapter the structure of SOD1 with eight ligands is presented. Each ligand 
is described bound to SOD1 in both the P21 and and C2221 space groups. These structures 
were solved using previously existing SOD1 models with PDB codes 2VOA 90 and 1UXL 
89 respectively. Four structures of L38V SOD1 were found to pack in the P212121 space 
group.  These  structures  were  solved  by isomorphous  phasing  using  a  pre-existing  but 
unpublished model of P212121 native L38V SOD1 which was itself solved by molecular 
replacement using the program MOLREP 115.
2.7 Refinement
Isomorphous phasing allows one to generate a rough electron density map of the protein-
ligand complex under investigation. At this point structure factors can be calculated from 
the model taking into account the sum of diffractive contributions from individual atoms 
(j) with elemental scattering factor (fj) at a particular position (xj, yj, zj) in the unit cell.
F hkl=∑
j=1
f j e
2Πi (hx j+ky j+lz j)
The  model  becomes  more  detailed  as  components  are  added  to  reflect  experimentally 
observed electron density. As a result the phases computed from it also improve and thus 
the subsequent model computed from the original structure factor amplitudes and latest 
phase information also improves. In this cycle of model refinement and structure factor 
recalculations  the  model  becomes  increasingly  a  mirror  of  the  real  molecule  with 
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calculated  amplitudes  │Fc│  approaching  observed  amplitudes│Fo│. The  structures 
presented in the following chapter  were constructed with successive rounds of  manual 
model building in COOT 116 and refinement with REFMAC5 117.
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Chapter III
Crystallographic screening of small molecules for SOD1 binding
3.1 SOD1 screening pipeline
Using a crystallographic approach to compound screening and lead optimisation we hope 
to find compounds that bind to and consequently change the pathogenic characteristic of 
SOD1, with the aim of producing target specific therapeutics. In practice this involves co-
crystallisation of SOD1 with a number of putative ligands and subsequent determination of 
the structure of the SOD1-ligand complex.
The screening of small molecules for SOD1 binding took place against the dimer interface 
mutant I113T. The II13T mutation was one of the first 11 SOD1 mutations implicated in 
ALS 17. It is one of the most common SOD1 gene mutations and has been reported in nine 
countries. It is by far the most common mutation in the UK 118,119 and is associated with 
extreme phenotypic variation 120,121 and incomplete penetrance 122. This mutant is known to 
be extremely prone to aggregation in vitro as a result of metal loss 78.
I113T SOD1 crystals in the P21 space group were grown from seed at pH 5. This crystal 
form is densely packed and can diffract up to atomic resolution 123,51, with 1.0 Å currently 
the  highest  documented  resolution,  and  is  resistant  to  low  concentrations  of  dimethyl 
sulfoxide  (DMSO).  If  binding  was  observed  in  the  crystal  structure  with  I113T  the 
compound was soaked into wild-type, L38V 17 and H48Q 55 SOD1 crystals at pH 5. L38V 
is located in the loop connecting strands 3 and 6 of the SOD1  β-barrel and H48Q is a 
copper site mutant. In order to discount ligand binding through crystal lattice contacts the 
compound was also tested against I113T SOD1 crystals in the C2221 space group grown at 
pH 8.  This  ligand  soaking pipeline  afforded a  robust  assessment  of  binding  against  a 
representative selection of SOD1 mutants at high resolution and at physiologically relevant 
conditions. As a result every ligand soaking experiment was repeated at least five times. A 
complete list of the compounds analysed for SOD1 binding is presented in Appendix IV.
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3.2 Small molecule library screen
An initial screen for SOD1 binding compounds met with limited success. The screen used 
was  the  Rigaku  Activesite  Library  of  384  diverse  compounds.  This  selection  of  low 
molecular  weight  compounds  is  solubilised  in  100%  DMSO.  The  crystal  soaking 
procedure must be carried out in a  buffer  solution that prevents crystals  dissolving.  In 
practice this means mixing the compound solution and the crystal soaking buffer prior to 
soaking. The majority of the compounds used in the screen were not soluble in less than 
100%  DMSO  unless  their  concentration  was  below  the  low  millimolar  range. 
Consequently, the amount of compound available for binding to SOD1 during the soaking 
experiment was also low and therefore few hits were discovered 123.
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3.3 4-(4-methyl-1,4-diazepan-1-yl)-2-(trifluoromethyl)quinazoline (MDTQ)
As part of their ongoing research into the pathogenesis and amelioration of SOD1 related 
fALS  Antonyuk et  al reported a diverse group of molecules which were found to bind 
SOD1  123.  One  of  these  compounds,  4-(4-methyl-1,4-diazepan-1-yl)-2-
(trifluoromethyl)quinazoline hereafter called MDTQ, was found to occupy a binding site 
over  the  SOD1  Trp32.  MDTQ  is  composed  of  a  quinazoline  ring  system  with  an 
homopiperazine group connected at C4 and a trifluoromethyl at C2 (Figure 3.1). MDTQ 
has good solubility in aqueous buffers removing the necessity to use strong solvents such 
as DMSO.
Figure 3.1. The structure of MDTQ (4-(4-methyl-1,4-diazepan-1-yl)-2-(trifluoromethyl) quinazoline).  The 
quinazoline numbering system is shown, Mr 310.14 g Mol-1.
In  the  structure  presented  by  Antonyuk  et  al 123, the  tri-fluromethyl  group  of  MDTQ 
interacts with L38V SOD1 through two hydrogen bonds with Glu100. The quinazolene 
double ring system was also hydrogen bonded with Ser98. MDTQ bound L38V SOD1 
with the long axis of its quinazoline ring system running parallel with the Trp32 indole 
group maximising any stacking interaction.
MDTQ was entered into the SOD1 screening pipeline in order to asses the methodology's 
efficacy, determine if MDTQ universally binds all SOD1 mutants and to characterise its 
pharmacophore properties. Table 3.1 shows the crystallographic statistics for five SOD1-
MDTQ structures.
Figure  3.2A indicates  the  position  of  MDTQ binding between strands  3  and 6  on  the 
surface of the I113T SOD1 Greek-key β-barrel. As previously reported the trifluoromethyl 
group protrudes into a cleft created by the side chains of Lys30, Glu100 and Ser98 (Figure 
3.2B). This group has possible hydrogen bonding interactions with the side chain hydroxyl 
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of  Ser98  and  the  backbone  amide  groups  of  Val31  and  Ile99  (Figure  3.2D).  Another 
hydrogen bond with the Glu100 carboxylic acid was postulated previously however in this 
structure the donor-acceptor distance is 4.6 Å. The Ser98 side chain also acts as a hydrogen 
bond donor to a MDTQ quinazoline ring nitrogen. These interactions are summarised in 
table 3.2.
SOD1 variant I113T I113T wild-type L38V H48Q
Resolution (Å) 1.29 2.00 2.20 1.45 1.59
Space group P21 C2221 P21 P212121 P21
pH 5.0 8.0 5.0 5.0 5.0
Unit cell parameters:
a (Å) 38.5 165.1 39.0 49.9 38.7
b (Å) 68.1 203.6 68.0 67.7 68.3
c (Å) 49.9 144.5 49.6 74.1 50.3
α (o) 90.0 90.0 90.0 90.0 90.0
β (o) 104.8 90.0 104.4 90.0 105.2
γ (o) 90.0 90.0 90.0 90.0 90.0
Completeness (%) 99.1 (95.6) 98.7 (98.5) 98.2 (92.0) 99.9 (99.5) 97.6 (91.5)
Redundancy 4.1 (3.5) 3.6 (3.5) 3.3 (3.0) 6.2 (5.6) 3.6 (3.6)
R-merge (%) 8.8 (65.5) 10.2 (58.9) 29.3 (45.1) 9.8 (67.6) 7.9 (24.3)
I/σ 9.54 (2.2) 9.51 (2.1) 3.1 (1.9) 9.8 (2.3) 10.1 (3.6)
Rfact / Rfree (%) 14.9 / 21.4 20.6 / 24.2 22.2 / 33.8 18.6 / 22.0 22.8 / 26.9
RMS bond (Å) 0.015 0.015 0.021 0.014 0.014
Table 3.1. Single crystal  X-ray diffraction data collection, processing and model refinement statistics for 
MDTQ bound to human recombinant SOD1.
By virtue of its dimeric nature, SOD1 contains two Trp32 binding sites per molecule. In 
the structure presented in Figure 3.2, MDTQ adopts a different conformation at each site. 
Hydrogen bonding interactions are preserved in both conformations with the exception of 
the  Ser98  hydrogen  bond  which  switches  acceptors  between  the  nitrogens  distal  and 
proximal to the MDTQ homopiperazine group (Figure 3.2B and C respectively). In both 
cases, binding is likely to be strengthened though aromatic  π-π interactions between the 
MDTQ quinazoline ring system and the indole moiety of Trp32. The homopiperazine ring 
extends into the solvent in each case. Figure 3.2B  shows good electron density around this 
group indicating a possible stabilising hydrogen bond with the Glu21 side chain carboxylic 
acid  group  although  the  donor-acceptor  distance  is  4.6  Å  (Figure  3.2D).  The  second 
conformation shows little electron density (Figure 3.2C) indicating this group is freely able 
to rotate around the N-C4 bond connecting it to the quinazoline rings.
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Figure 3.2. MDTQ bound to I113T SOD1. (A) MDTQ with respect to the SOD1 dimer in grey and light grey,  
strands 3 and 6 of the SOD1 β-barrel are coloured purple and green respectively. (B) 2Fo-Fc electron density 
map of MDTQ contoured at 1σ at the Trp32 binding site with the SOD1 surface coloured by amino acid 
hydrophobicity according Eisenberg's consensus hydrophobicity scale 124 and (C) the second conformation of 
MDTQ at the Trp32 of the opposing I113T SOD1 dimer. (D) Hydrogen bonding between I113T SOD1 and  
MDTQ shown with black dashed lines.
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Figure  3.3.  MDTQ bound to  multiple  SOD1 mutants. 2Fo-Fc electron  density maps contoured  at  1σ  of 
MDTQ bound at the Trp32 site in (A) I113T SOD1 pH 8 C2221 crystal structure (B) L38V SOD1  in the 
P212121 form, (C) wild-type SOD1 and (D) H48Q SOD1 grown at pH 5 in the P21 form.
Donor I113T wtSOD1 L38V H48Q I113T pH8 Acceptor
Ser98-OH 2.7 Å 3.0 Å 2.7 Å 2.9 Å 2.8 Å N-Quinazoline
Ser98-OH 2.7 Å 2.6 Å 2.8 Å 2.5 Å 2.5 Å F-Trifluoromethyl
Ile99-NH 3.6 Å 3.7 Å 3.4 Å 3.8 Å 3.3 Å F-Trifluoromethyl
Val31-NH 3.2 Å 3.5 Å 4.1 Å 3.3 Å 3.2 Å F-Trifluoromethyl
Glu100-COOH 4.6 Å 4.2 Å 4.7 Å 3.1 Å 3.9 Å F-Trifluoromethyl
Table 3.2. Summary of potential hydrogen bonding in between MDTQ and SOD1. In the case of the I113T 
P21 structure values indicate the canonical orientation presented in Figure 3.2B.
Figure  3.3  describes  the  binding  of  MDTQ to  three  SOD1 variants.  In  each  case  the 
MDTQ molecule is found in the published orientation. Electron density for the ligand is 
good indicating that binding to SOD1 is not pH or SOD1 mutant dependent.
To probe the nature of MDTQ binding three derivatives with modified pharmacophore 
properties were synthesised. The following two sections describe the binding of two of 
these compounds, MPQ and MDQ, to recombinant SOD1.
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3.4 4-(4-methylpiperazin-1-yl)quinazoline (MPQ)
The  quinazoline  based  compound  4-(4-methylpiperazin-1-yl)quinazoline  (MPQ)  differs 
from MDTQ in that the trifluoromethyl group at C2 is not present and the homopiperazine 
at C4 is replaced with a methylpiperazine (Figure 3.4). Table 3.3 shows crystallographic 
statistics for various SOD1 proteins complexed with MPQ.
Figure 3.4.  The structure of MPQ (4-(4-methylpiperazin-1-yl)quinazoline).  The quinazoline numbering is 
system shown, Mr 228.14 g Mol-1.
SOD1 variant I113T I113T wild-type L38V H48Q
Resolution (Å) 1.24 1.93 1.35 1.33 1.53
Space group P21 C2221 P21 P212121 P21
pH 5.0 8.0 5.0 5.0 5.0
Unit cell parameters:
a (Å) 38.7 166.3 38.8 50.1 38.6
b (Å) 68.1 203.8 68.5 67.8 68.1
c (Å) 50.0 144.5 50.0 74.4 49.6
α (o) 90.0 90.0 90.0 90.0 90.0
β (o) 104.7 90.0 104.5 90.0 104.5
γ (o) 90.0 90.0 90.0 90.0 90.0
Completeness (%) 99.9 (99.9) 99.5 (95.5) 94.1 (69.6) 95.2 (77.3) 95.2 (94.4)
Redundancy 4.1 (3.4) 3.7 (3.0) 3.47 (2.6) 6.08 (3.37) 3.7 (3.8)
R-merge (%) 8.2 (68.9) 9.2 (52.0) 5.4 (42.8) 8.4 (59.8) 7.2 (11.5)
I/σ 14.4 (1.7) 12.3 (2.0) 13.3 (2.2) 10.81 (1.73) 12.2 (3.8)
Rfact / Rfree (%) 13.9 / 17.5 17.2 / 20.4 13.6 / 18.1 17.3 / 23.3 19.4 / 23.2
RMS bond (Å) 0.014 0.015 0.013 0.013 0.014
Table 3.3. Single crystal  X-ray diffraction data collection, processing and model refinement statistics for 
MPQ bound to SOD1.
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Figure 3.5. MPQ bound to I113T SOD1. (A) MPQ with respect to the SOD1 dimer in grey and light grey,  
strands 3 and 6 of the SOD1 β-barrel are coloured purple and green respectively. (B) 2Fo-Fc electron density 
map of MPQ contoured at  1σ at  the Trp32 binding site with the SOD1 surface coloured by amino acid 
hydrophobicity and (C) Stick diagram of MPQ bound over the I113T SOD1 Trp32.
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Figure 3.5A shows the mode of binding of MPQ to I113T on the surface of strand 3 of the 
SOD1 β-barrel. This compound occupies roughly the same space as MDTQ roughly 3.5 Å 
above the Trp32 indole. MPQ binding at  this site differs however from that of MDTQ 
presented in the previous section in that the quinazoline nitrogen atoms are not involved in 
hydrogen bonding with SOD1 and face out from the β-barrel.  The methylpiperazine is 
positioned between the side-chains of Glu21 and Lys30, 3.5 Å from each, with a possible 
hydrogen bond between the Glu21 carboxyl and  methylpiperazine nitrogen (Figure 3.5C).
Figure 3.6.  MPQ bound to multiple SOD1 mutants. 2Fo-Fc electron density maps contoured at 1σ of  MPQ 
bound at the Trp32 site in (A) I113T SOD1 pH 8 C2221 crystal structure (B) L38V SOD1 in the P212121 form, 
(C) wild-type SOD1 and (D) H48Q SOD1 grown at pH 5 in the P21 form.
MPQ was analysed for binding against other SOD1 variants as per the screening pipeline 
described previously. In each instance, MPQ binds at the Trp32 site in the orthodox fashion 
with N1 of the quinazoline rings forming a hydrogen bond with Ser98 and a potential 
hydrogen  bond  between  MPQ's  methylpiperazine  group  and  Glu21  (Figure  3.6).  This 
hydrogen bond has length 2.9 - 3.4 Å and in the case of L38V SOD1 induces a change in  
the conformation of Glu21 drawing its side-chain carboxyl closer to the methylpiperazine 
nitrogen (Figure 3.6B).
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3.5 4-(4-methyl-1,4-diazepan-1-yl)quinazoline (MDQ)
Figure 3.7 describes the structure of 4-(4-methyl-1,4-diazepan-1-yl)quinazoline (MDQ). 
This compound is very similar to MDTQ with an unmodified homopiperazine group at C4 
but the trifluoromethyl at quinazoline ring position C2 is removed. Like the previous two 
compounds, MDQ has good solubility in aqueous buffers. This compound was entered in 
to the SOD1 screening pipeline (Table 3.4) and, as expected, was found to interact with 
SOD1 at the Trp32 site on the surface of strand 3 of the β-barrel (Figure 3.8A).
Figure 3.7. The structure of MDQ (4-(4-methyl-1,4-diazepan-1-yl)quinazoline). The quinazoline numbering 
system is shown, Mr 242.15 g Mol-1.
Figure 3.8B shows the unbiased electron density of the MDQ quinazoline rings above and 
parallel to the Trp32 indole. In contrast to MPTQ and MPQ, there is no electron density 
associated  with  the   homopiperazine  group outside  outside  the  N-C4 bond.  This  bond 
cannot  move  independently  of  the  quinazoline  system  and  allows  us  to  positively 
determine the orientation of the MDQ molecule. There are no hydrogen bonds between this 
compound and SOD1 (Figure 3.8C) indicating that the only force keeping this molecule in 
place is a hydrophobic interaction between the aromatic Trp32 indole and the quinazoline 
ring  moieties.  Repeating  this  binding  experiment  against  other  SOD1  variants  yields 
similar results (Figure 3.9B, C and D). At pH 8 however there is clear electron density 
around the homopiperazine group although there are no hydrogen bonding partners within 
a reasonable distance that could prevent this groups free rotation (Figure 3.9A).
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Variant I113T I113T wild-type L38V H48Q
Resolution (Å) 1.22 2.29 1.35 1.21 1.6
Space group P21 C2221 P21 P212121 P21
pH 5.0 8.0 5.0 5.0 5.0
Unit cell parameters:
a (Å) 38.0 165.0 38.3 50.6 38.8
b (Å) 68.2 202.9 68.1 68.1 68.3
c (Å) 49.0 144.1 49.3 74.3 50.4
α (o) 90.0 90.0 90.0 90.0 90.0
β (o) 104.1 90.0 104.3 90.0 105.4
γ (o) 90.0 90.0 90.0 90.0 90.0
Completeness (%) 97.3 (87.2) 99.4 (96.8) 95.5 (76.8) 98.1 (90.9) 96.4 (95.3)
Redundancy 3.5 (2.8) 7.1 (6.5) 3.4 (2.3) 8.9 (4.9) 3.6 (3.8)
R-merge (%) 8.0 (52.2) 14.9 (83.9) 7.1 (35.6) 9.5 (75.7) 14.0 (48.4)
I/σ 9.7 (1.9) 11.52 (2.14) 10.52 (2.14) 12.82 (2.06) 6.3 (2.3)
Rfact / Rfree (%) 12.5 / 15.9 16.4 / 21.7 16.5 / 21.8 15.7 / 20.1 25. 6 / 30.1
RMS bond (Å) 0.014 0.015 0.014 0.012 0.016
Table 3.4. Single crystal  X-ray diffraction data collection, processing and model refinement statistics for 
MDQ bound to SOD1.
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Figure 3.8. MDQ bound to I113T SOD1. (A) MDQ with respect to the SOD1 dimer in grey and light grey,  
strands 2,  3 and 6 of the SOD1  β-barrel  are coloured yellow, purple and green respectively.  (B) 2Fo-Fc 
electron density map of MDQ contoured at 1σ at the Trp32 binding site with the SOD1 surface coloured by 
amino acid hydrophobicity and (C) Stick model of I113T SOD1 with MDQ bound over Trp32.
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Figure 3.9. MDQ bound to multiple SOD1 mutants. 2Fo-Fc electron density maps contoured at 1σ of MDQ 
bound at the Trp32 site in (A) I113T SOD1 pH 8 C2221 crystal structure (B) L38V SOD1 in the P212121 form, 
(C) wild-type SOD1 and (D) H48Q SOD1 grown at pH 5 in the P21 form.
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3.6 4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)quinazoline (MPTQ)
The  compound  presented  in  Figure  3.10,  4-(4-methylpiperazin-1-yl)-2-
(trifluoromethyl)quinazoline (MPTQ)  is another quinazoline derivative which differs from 
the original MDTQ compound published by Antonyuk et al 123 only by the omission of a 
carbon  and  two hydrogens  from the  homopiperazine  moiety to  form methylpiperazine 
(Figure 3.10). This change brings about a reduction in molecular mass from 310.14 to 
296.12 gMol-1 and an increase in ClogP of 2.75 to 2.77 for MDTQ and MPTQ respectively. 
MPTQ has a much lower solubility in water than MDTQ despite such small changes in 
physical characteristics. Consequentially, this compound could not be used at the 50 mM 
crystal soaking concentration which is standard in much published ligand soaking work 
and has been used thoughout this study. In practice the maximum concentration at which 
MPTQ could be used was 1 mM as there is a trade-off between crystallisation precipitant 
and solubilising agent concentrations that can be used in the soaking buffer, in this case 
ammonium sulphate and DMSO.
Figure  3.10.  The  structure  of  MPTQ  (4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)quinazoline).  The 
quinazoline numbering system is shown, Mr 296.12 gMol-1.
The structure presented in Figure 3.11 and described in Table 3.5 is the result of one such 
experiment using low concentration MPTQ soaking in to I113T SOD1 at pH 5. While there 
is  little  density  around  both  the  quinazoline  and  methylpiperazine  groups,  the 
trifluoromethyl group can be seen in the Lys30-Ser98-Glu100 pocket. As with MDTQ, this 
compound should make hydrogen bonds with the backbone amide groups of Val31 and 
Ile99 together with the Glu100 carboxylic acid group. Low occupancy of MPTQ at the 
Trp32 site was replicated in L38V, H48Q and wild-type SOD1 crystal structures.
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Figure 3.11.  MPTQ bound to I113T SOD1. 2Fo-Fc electron density map contoured at 1σ of  MPTQ with 
partial occupancy at the Trp32 site in the P21 crystal structure I113T SOD1 at pH 5.
Variant I113T
Resolution (Å) 1.57
Space group P21
pH 5.0
Unit cell parameters:
a (Å) 30.6
b (Å) 68.0
c (Å) 50.6
α (o) 90.0
β (o) 105.6
γ (o) 90.0
Completeness (%) 98.1 (90.6)
Redundancy 3.6 (3.1)
R-merge (%) 8.6 (62.9)
I/σ 11.1 (2.1)
Rfact / Rfree (%) 17.4 / 21.5
RMS bond (Å) 0.015
Table 3.5. Single crystal  X-ray diffraction data collection, processing and model refinement statistics for 
MPTQ bound to SOD1.
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3.7 Quinazoline Summary
The quinazoline ring system is a versatile scaffold used in many therapeutic applications 
including  antibacterials  125,  antimalarials  126,  cancer  treatments  127 and  analgesics  128. 
Antonyuk et al previously documented an interaction between SOD1 and the quinazoline 
derivative  4-(4-methyl-1,4-diazepan-1-yl)-2-(trifluoromethyl)quinazoline  (MDTQ)  123. 
Here we have observed this compound binding to wild-type and fALS associated SOD1 
proteins in  different crystal  environments.  To probe the nature of this  interaction three 
similar compounds were synthesized, varying only by substitution at C2 and C4, and their 
binding to SOD1 was analysed. All three compounds occupy a similar binding site over 
Trp32 and, where compound solubility was not a problem, showed good electron density 
indicating a high level of occupancy. When the C2 trifuoromethyl group is removed these 
compounds are not locked in position by extensive hydrogen bonding the Ile99, Val31 and 
Glu100. All four compounds benefit strongly from a hydrophobic stacking interaction with 
the Trp32 indole. This maybe the only force keeping MPQ and MDQ in place, other than a 
possible hydrogen bond with the carboxyl side chain of Glu100. Substitution at C4 has 
little effect on binding and in many cases this group is able to rotate around the N-C4 
covalent bond.
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3.8 5-Fluorouridine
Fluorinated pyrimidine analogues, such as 5-fluorouracil,  are widely used as anti-tumor 
therapeutics. 5-Fluorouracil is a member of the antimetabolite class of cancer treatments 
and exerts an effect by conversion to 5-fluorouridine which is in turn phosphorylated. The 
resulting  compound  forms  a  stable  complex  with  thymidylate  synthase  inhibiting 
deoxythymidine monophosphate synthesis or is incorporated into nascent mRNA where it 
disrupts much of its normal function 129.
5-Fluorouridine is a nucleoside derivative composed of a single uracil ring substituted at 
C5 with fluorine and a ribose ring at N3 (Figure 3.12). While it is a more potent anti-tumor 
agent than 5-fluorouracil and the highly similar 5-fluoro-2'deoxyuridine it is not in clinical 
use due to strong associated side effects.
Figure 3.12. The structure of 5-fluorouridine. The pyrimidine numbering system is shown. Mr 262.02 gMol-1.
Nowak et al highlighted 5-fluorouridine as a potent inhibitor of in vitro SOD1 aggregation 
130. This group used  in silico methods to find compounds with a potential  to bind at  a 
hydrophobic pocket at the SOD1 dimer interface centred on Val7, Gly146 and Val147 from 
opposing monomers 131. By occupying this site a perceived instability in the SOD1 mutant 
dimer  that  promotes  monomerisation  was  abrogated  and  aggregation  propensity  was 
returned to a level equivalent to that seen in the wild-type protein. The uracil moiety was 
prevalent in this first group of compounds which were then further modified for greater 
specificity, activity and improved ADME properties 130. 5-Fluorouridine was a member of 
this second cohort and was observed to reduce conversion of the A4V mutant SOD1 dimer 
to  higher  molecular  weight  aggregates  to  approximately  5  %  over  a  48  hour  period 
compared with 50 % over 4 hours for A4V SOD1 solely.
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5-Fluorouridine and other compounds from both studies described above 130,131 have great 
promise as SOD1 therapeutic leads but have never been directly visualised  in situ at the 
Val7-Gly146-Val147 pocket. This compound was entered into the SOD1 screening pipeline 
not only to gain important structural information regarding its mode of binding with the 
aim of further optimisation but also to gain an improved understanding of SOD1 related 
fALS  pathogenesis.  Crystallographic  data  relating  to  this  compound  bound  to  several 
SOD1 variants are presented in Table 3.6.
Variant I113T I113T wild-type L38V H48Q
Resolution (Å) 1.06 1.95 1.28 1.24 1.53
Space group P21 C2221 P21 P212121 P21
pH 5.0 8.0 5.0 5.0 5.0
Unit cell parameters:
a (Å) 38.0 165.2 38.6 50.0 38.7
b (Å) 68.1 203.2 68.2 67.6 68.0
c (Å) 49.1 144.4 50.2 74.0 50.5
α (o) 90.0 90.0 90.0 90.0 90.0
β (o) 104.2 90.0 105.1 90.0 105.6
γ (o) 90.0 90.0 90.0 90.0 90.0
Completeness (%) 87.8 (68.2) 99.9 (99.5) 96.4 (74.5) 91.0 (56.0) 99.7 (99.7)
Redundancy 2.4 (1.6) 7.0 (6.5) 3.5 (2.5) 5.8 (2.4) 3.6 (3.6)
R-merge (%) 7.0 (41.7) 11.9 (68.1) 5.4 (47.5) 7.4 (48.7) 8.0 (26.2)
I/σ 7.5 (1.5) 12.0 (2.8) 18.7 (1.9) 12.8 (1.7) 9.7 (4.1)
Rfact / Rfree (%) 16.2 / 20.0 17.6 / 20.9 12.8 (17.8) 15.0 / 19.0 20.7 / 24.4
RMS bond (Å) 0.015 0.014 0.014 0.014 0.015
Table 3.6 Single crystal X-ray diffraction data collection, processing and model refinement statistics for 5-
fluorouridine bound to SOD1.
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Figure 3.13. The I113T dimerisation region hydrophobic pocket after crystal soaking with 5-fluorouridine. 
(A) The position of the Val7-Gly146-Val147 pocket with residues highlighted cyan and (B) 2Fo-Fc electron 
density maps contoured at 1σ of solvent in this pocket in the I113T SOD1 crystal structure after soaking with 
50 mM 5-fluorouridine for 2 hours. The pocket is shown from two angles with no sign of electron density 
corresponding to 5-fluorouridine.
Figure 3.13A shows the location of the Val7-Gly146-Val147 pocket at the SOD1 dimer 
interface. This pocket is again shown in Figure 3.13B with electron density from the solved 
crystal structure of I113T SOD1 soaked in 50 mM 5-fluorouridine for 2 hours. While there 
is an abundance of water molecules at this site there is no electron density which could 
represent 5-fluorouridine. Soaking this compound into different SOD1 variants at both pH 
5 and 8 achieved the same negative result at this site.
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Figure 3.14. 5-Fluorouridine bound to I113T SOD1. (A) 5-Fluorouridine with respect to the SOD1 dimer in 
grey  and  light  grey,  strands  2,  3  and  6  of  the  SOD1  β-barrel  are  coloured  yellow,  purple  and  green 
respectively. (B) 2Fo-Fc electron density map of 5-fluorouridine contoured at 1σ at the Trp32 binding site 
with the SOD1 surface coloured by amino acid hydrophobicity and (C) Hydrogen bonding between I113T 
SOD1 and 5-fluorouridine shown with black dashed line.
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Figure 3.15. 5-Fluorouridine bound to multiple SOD1 mutants. 2Fo-Fc electron density maps contoured at 1σ 
of 5-fluorouridine bound at the Trp32 site in (A) I113T SOD1 pH 8 C2221 crystal structure (B) L38V SOD1 
in the P212121 form, (C) wild-type SOD1 and (D) H48Q SOD1 grown at pH 5 in the P21 form.
During the course of structure refinement it became clear that 5-fluorouridine does bind 
SOD1  at  the  Trp32  site  (Figure  3.14).  This  is  not  unsurprising  given  the  ability  of 
tryptophan  to  engage  molecules  in  non-specific  stacking  interactions  however  5-
fluorouridine also potentially makes a hydrogen bond between the C2 carbonyl and the 
Ser98 side-chain (Table 3.7).
Donor I113T wtSOD1 L38V H48Q Acceptor
Ser98-OH 3.7 Å 3.9 Å 4.3 Å 4.4 Å O=C2-5-Fluorouridine
Table 3.7 Summary of potential hydrogen bonding between 5-fluorouridine and SOD1 at the Trp32 site. A 
value is not shown for 5-fluorouridine bound in the C2221 structure as the hydrogen bond distances are too 
large.
5-Fluorouridine's interaction with the I113T Trp32 site is mediated though the pyrimidine 
ring and its substituents. In the structure presented there is very little electron density that 
can be attributed to the ribose ring and there are no available bonding partners indicating it 
is freely able to rotate around N3-C bond.
Analysis of 5-fluorouridine bound at the Trp32 site in crystal structures of L38V, H48Q 
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and  wild  type  SOD1 in  the  P21 crystal  form grown at  pH 5  indicates  this  binding is 
repeatable and consistent in form (Figure 3.15B, C and D). In each case there is good 
electron density associated with the pyrimidine group, which forms two hydrogen bonds 
with the SOD1 Lys30 and Ser98 side-chains. Conversely, 5-fluorouridine binding at pH 8 
is of a slightly different character. In this case the uracil ring is rotated over Trp32 bringing 
the  C6  carbonyl  into  hydrogen  bonding  distance  (3.6  Å)  with  the  Glu21  side-chain 
carboxyl. Again the ribose group shows little electron density when contoured at 1σ.
To summarise,  5-fluorouridine was predicted to bind to SOD1 at a pocket close to the 
dimerisation  region.  This  compound  was  observed  to  effectively inhibit  SOD1 mutant 
aggregation  in vitro  130. Here we are unable to find any evidence of that this compound 
binds at the predicted site. This is despite numerous crystal soaking experiments against 
several SOD1 variants. One can however observe some electron density attributable to 5-
fluorouridine at  the Trp32 binding site described by  Antonyuk et  al 123 and explored in 
detail in the previous sections.
50
3.9 Isoproteranol
Isoproteranol is a licensed sympathomimetic inotropic drug used in the treatment of several 
cardiac conditions and asthma 132 although in the latter case it has largely been superseded 
by  newer  therapeutics  due  to  complications  arising  from  dosing  133.  It  is  a  synthetic 
catecholamine and isopropyl derivative of epinephrine (Figure 3.16) which acts on the β1 
and β2 adrenergic receptor.
Figure 3.16. The structure of isoproteranol (also known as: Isoprenaline, Isuprel and Medihaler-iso). 211.3 
gMol-1.
Isoproteranol  was  also  proposed  as  a  SOD1  binding  compound  targeted  to  the  Val7-
Gly146-Val147  pocket  130.  This  is  particularly  interesting  in  light  of  recent  findings 
implicating  isoproteranol  in  effective  down regulation  of  SOD1 mRNAs in  Wistar  rat 
myocardium tissue following 7 days of repeated dosing 134. While this effect has not been 
researched in  man and may result  from a  number  possible  non-specific  processes  this 
compound is clearly worth investigation in regard to its potential interaction with SOD1. 
Isoproteranol was soaked into crystals of SOD1 and the bound structures were analysed for 
ligand binding (Table 3.8).
Figure 3.17 shows the Val7-Gly146-Val147 pocket of I113T SOD1 after crystal soaking 
with isoproteranol. The result is much the same as that described in the previous section 
dealing  with  5-fluorouridine,  while  electron  density  associated  with  ordered  water 
molecules is clearly visible there  is nothing which represents the ligand.
Isoproteranol can however be found at four other unique sites in this structure. Three of 
these are in regions where the ligand makes contacts with more than one SOD1 dimer and 
can be discounted as artefacts of crystal packing. Figure 3.17 describes the remaining site 
in a groove created by the short loop II connecting strands 2 and 3 of SOD1  β-barrel. 
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Binding is repeatable,  not SOD1 mutant specific and pH independent (Figure 3.18 and 
3.19).
Variant I113T I113T wild-type L38V H48Q
Resolution (Å) 1.45 2.2 1.34 1.53 1.53
Space group P21 C2221 P21 P21 P21
pH 5.0 8.0 5.0 5.0 5.0
Unit cell parameters:
a (Å) 37.9 165.1 38.3 38.0 38.2
b (Å) 68.0 203.5 68.0 67.8 67.9
c (Å) 49.3 144.6 50.5 49.9 49.7
α (o) 90.0 90.0 90.0 90.0 90.0
β (o) 104.0 90.0 105.3 104.6 104.4
γ (o) 90.0 90.0 90.0 90.0 90.0
Completeness (%) 98.0 (94.2) 99.7 (98.6) 98.7 (87.3) 99.7 (99.7) 99.7 (99.7)
Redundancy 3.6 (3.4) 7.4 (7.3) 3.79 (3.27) 3.5 (3.6) 3.5 (3.6)
R-merge (%) 5.3 (26.0) 14.9 (91.2) 6.8 (42.1) 11.1 (31.3) 7.1 (16.0)
I/σ 15.2 (4.3) 13.32 (2.82) 10.99 (2.60) 6.9 (3.1) 11.8 (6.1)
Rfact / Rfree (%) 15.7 / 18.8 19.5 / 23.1 18.1 / 19.7 24.3 / 30.0 20.0 / 22.8
RMS bond (Å) 0.016 0.014 0.015 0.015 0.015
Table 3.8. Single crystal  X-ray diffraction data collection, processing and model refinement statistics for 
isoproteranol bound to SOD1.
Figure 3.17. The I113T dimerisation region hydrophobic pocket after crystal soaking with isoproteranol. 2Fo-
Fc electron density map contoured at 1σ of the I113T SOD1 Val7-Gly146-Val147 pocket with solvent after 2 
hours soak in 50 mM isoproteranol.
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Figure 3.18. Isoproteranol bound to I113T SOD1. (A) Isoproteranol with respect to the SOD1 dimer in grey 
and light grey, strands 2, 3 and 6 of the SOD1 β-barrel are coloured yellow, purple and green respectively. 
(B) 2Fo-Fc electron density map of isoproteranol contoured at 1σ at the β-barrel loop II site with the SOD1 
surface  coloured  by  amino  acid  hydrophobicity and  (C)  Hydrogen  bonding  between  I113T SOD1  and 
isoproteranol shown with black dashed lines. A single water molecule is also shown as a red sphere.
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Figure 3.19. Isoproteranol bound to multiple SOD1 mutants. 2Fo-Fc electron density maps contoured at 1σ of 
the loopII/catecholamine pocket with Isoproteranol bound in (A) I113T SOD1 pH 8 C2221 crystal structure 
(B) L38V SOD1 , (C) wild-type SOD1 and (D) H48Q SOD1 grown at pH 5 in the P21 form.
Donor I113T wtSOD1 L38V H48Q I113T pH8 Acceptor
Isoproteranol C1-OH 2.4 Å 2.6 Å 2.6 Å 2.5 Å 3.6 Å COOH-Glu100
Isoproteranol C1-OH 3.4 Å 3.2 Å 3.2 Å 3.4 Å 3.4 Å O=C-Pro28
Isoproteranol C2-OH 2.8 Å 2.8 Å 2.7 Å 2.9 Å 3.1 Å O=C-Pro28
Isoproteranol C2-OH 3.1 Å 3.1 Å 3.2 Å 3.2 Å 3.4 Å O=C-Glu21
Isoproteranol C2-OH 3.3 Å 3.4 Å 3.3 Å 3.4 Å 3.3 Å H2O
Isoproteranol tail-OH 3.1 Å 3.6 Å 4.3 Å 3.1 Å 4.7 Å O=C-Glu21
Isoproteranol tail-NH 3.5 Å 3.6 Å 3.3 Å 4.1 Å 3.7 Å O=C-Glu21
Table 3.9. Summary of potential hydrogen bonding interactions between SOD1 and isoproteranol in the loop 
II binding site.
This site is close to but distinct from the Trp32 binding site and the interaction has several 
features that distinguish it from those described in the previous sections. Isoproteranol sits 
in a hydrophilic groove created by Glu21, Lys23, Pro28, Lys30 and Glu100. The catechol 
head group is an obvious hydrogen bond donor to the carboxyl and carbonyl groups of 
Glu21, Glu100 and Pro28 together with a single water molecule which fills the groove 
adjacent to Pro28 (Table 3.9). Also, the amine and hydroxyl groups of the tail interact with 
the  Glu21  carboxyl.  The  isopropyl  tail  sits  above  Trp32  and  may  benefit  from  a 
54
hydrophobic interaction with the Trp32 indole however its occupancy is lower than the rest 
of the molecule indicating a degree of flexibility. In an unbound SOD1 structure the Lys30 
side-chain is able to move freely and is not visible after the β or γ carbon. Here space is 
limited by the presence of isoproteranol and the fully visible Lys30 side chain is forced to 
move towards Ser98. Other than this deformation the SOD1 dimer remains unperturbed 
with a  whole molecule RMSD of  0.26  Å compared with the atomic resolution crystal 
structure of wild-type SOD1 (2C9V) 51 (Figure 3.20).
Figure 3.20. Comparison of I113T SOD1 in the native and isoproteranol bound states. Structural alignment,  
RMSD = 0.25  Å, of I113T SOD1 with isoproteranol bound at the loop II site (blue and orange) with the  
structure of wild-type SOD1 (2C9V) (green). In each case the protein backbone is represented as a ribbon.
To summarise, we find that isoproteranol does not occupy the Val7-Gly146-Val147 pocket 
in any of the SOD1 structure presented here. In each of these structures, isoproteranol can 
be  found at  multiple  positions  some of  which  are  attributed  to  crystal  lattice  contacts 
however one site is not lattice dependent. Ligand binding at this loop II site is likely to 
create  several  hydrogen bonds with  the  protein  and each of  the  ligand's  four  possible 
hydrogen bond donor groups are involved in this interaction.
The  elucidation  of  a  catechol  binding site  at  loop II  of  the  SOD1  β-barrel  opens  the 
possibility to bind a large number of biologically relevant molecules in this position. What 
follows is a description of two such compounds; the hormones adrenaline and dopamine.
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3.10 Adrenaline
Adrenaline is a member of the biogenic amine group of excitatory neurotransmitters and 
acts on the  α  and  β adrenergic receptors. It is found in the neurons of the medulla and 
project into the thalamus and hypothalamus. Neurones that use adrenaline are found less 
frequently in the brain than those that utilise the other catecholamine neurotransmitters 135. 
Adrenaline  is  a  licensed  drug  and  used  frequently  in  the  treatment  of  asthma  136, 
bronchiolitis 137, anaphylaxis 138 and angioedema 139.
Adrenaline  is  structurally  very  similar  to  isoproteranol;  a  catechol  head  group  with 
hydroxyl and amine substitutions in the tail. In fact the only difference between these two 
drugs is the presence of an isopropyl group at the terminus of the molecules tail (Figure 
3.21).  This  similarity  ensured  that  crystal  soaking  experiments  would  be  successful 
however adrenaline has low solubility in aqueous solutions at neutral pH due to a lack of 
polarity.  This characteristic prevented an assessment of adrenaline binding to SOD1 at 
physiological pH. Crystallographic statistics for adrenaline bound in SOD1 crystals grown 
at pH 5 are presented in Table 3.10 and the related structures displayed in Figures 3.22 and 
3.23.
Figure 3.21. The structure of adrenaline (epinephrine, Twinject and Epipen). Mr 183.2 gMol-1.
Figure 3.22A and B indicate that, as expected, adrenaline binds in the same loop II groove 
as isoproteranol. Figure 3.22C and Table 3.11 describe the hydrogen bonding interactions 
between I113T SOD1 and adrenaline. Glu21, Pro28, Glu100 and the loop II ordered water 
molecule  all  act  as  hydrogen  bond  acceptors  in  partnership  with  adrenaline's  catechol 
hydroxyls. The carboxyl side-chain of Glu21 also interacts with the adrenaline's tail amine 
and hydroxyl groups. Comparison with the hydrogen bonds made by isoproteranol reveals 
these interactions are conserved with only slight changes in bond lengths discernible.
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Variant I113T wild-type L38V H48Q
Resolution (Å) 0.98 1.6 1.25 1.49
Space group P21 P21 P21 P21
pH 5.0 5.0 5.0 5.0
Unit cell parameters:
a (Å) 38.3 38.4 38.5 38.4
b (Å) 68.1 68.3 68.2 68.2
c (Å) 50.2 50.8 50.7 50.2
α (o) 90.0 90.0 90.0 90.0
β (o) 104.7 105.0 105.9 105.0
γ (o) 90.0 90.0 90.0 90.0
Completeness (%) 97.0 (71.3) 99.6 (99.6) 97.9 (89.3) 99.7 (99.0)
Redundancy 3.6 (2.0) 2.8 (2.7) 3.5 (2.7) 3.6 (3.6)
R-merge (%) 4.4 (51.7) 9.2 (44.8) 7.6 (41.4) 6.7 (15.9)
I/σ 14.7 (4.16) 6.3 (1.9) 9.4 (2.3) 13.0 (6.6)
Rfact / Rfree (%) 13.8 / 15.4 21.4 / 25.9 22.2 / 25.1 20.2 / 22.9
RMS bond (Å) 0.014 0.014 0.014 0.015
Table 3.10.Single crystal X-ray diffraction data collection, processing and model refinement statistics for  
adrenaline bound to SOD1.
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Figure 3.22. Adrenaline bound to I113T SOD1. (A) Adrenaline with respect to the SOD1 dimer in grey and 
light grey, strands 2, 3 and 6 of the SOD1 β-barrel are coloured yellow, purple and green respectively. (B) 
2Fo-Fc electron density map of adrenaline contoured at 1σ at the Trp32 binding site with the SOD1 surface 
coloured by amino acid hydrophobicity and (C) hydrogen bonding between I113T SOD1 and adrenaline 
shown with black dashed lines. A single water molecule is also shown as a red sphere.
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Figure 3.23. Adrenaline bound to multiple SOD1 mutants. 2Fo-Fc electron density maps contoured at 1σ of 
adrenaline bound at the loop II site in (A) L38V SOD1 in the P212121 form, (B) wild-type SOD1 and (C) 
H48Q SOD1 grown at pH 5 in the P21 form.
Donor I113T wtSOD1 L38V H48Q Acceptor
Adrenaline C1-OH 2.6 Å 2.5 Å 2.8 Å 2.6 Å COOH-Glu100
Adrenaline C1-OH 3.2 Å 3.1 Å 3.4 Å 3.2 Å O=C-Pro28
Adrenaline C2-OH 2.8 Å 2.7 Å 2.7 Å 2.7 Å O=C-Pro28
Adrenaline C2-OH 3.2 Å 3.2 Å 3.3 Å 3.2 Å O=C-Glu21
Adrenaline C2-OH 3.4 Å 3.3 Å 3.3 Å 3.4 Å H2O
Adrenaline tail-OH 4.0 Å 4.3 Å 2.8 Å 3.9 Å COOH-Glu21
Adrenaline tail-NH 4.0 Å 3.3 Å 3.9 Å 3.5 Å COOH-Glu21
Table 3.11. Summary of potential hydrogen bonding interactions between I113T SOD1 and adrenaline in the 
loop II binding site.
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3.11 Dopamine
Dopamine is a biogenic amine neurotransmitter and a critical intermediate in the synthesis 
of adrenaline and noradrenaline from tyrosine and L-dihydroxyphenylalanine  135. Unlike 
isoproteranol and adrenaline, dopamine acts upon specific G-protein coupled receptors in 
dopaminergic  neurones  rather  than  adrenergic  receptors.  These  neurones  are  found 
throughout the brain, where they are involved in working memory  140,  the heart,  where 
stimulation can increase myocardial contractility and cardiac output, and the kidneys where 
they effect diuresis and natriuresis 141.
The dopaminergic nervous system is implicated in a plethora of common disease states. 
These include: hypertension, obesity 141, attention deficit disorder 142, schizophrenia 143 and 
drug dependence  144.  These  neurones  are  also  critically  affected  in  Parkinson's  disease 
(PD). Analogous to ALS, PD involves the selective death of a subset of CNS neurones in 
the brain's substantia nigra. While the etiology of PD is not clearly understood there are 
indications  that  an  interaction  between  dopamine  and  α-synuclein  promotes  amyloid 
deposition and cell death 145.
Figure 3.24. The structure of dopamine. Mr 153.2 gMol-1.
Like isoproteranol and adrenaline, dopamine follows the catecholamine blueprint with a 
catechol  head  group attached  to  a  tail  substituted  with  an  amine  group (Figure  3.24). 
Dopamine does not contain a tail hydroxyl as seen in the previous two compounds and this 
reduces the number of potential hydrogen bonds between the ligand and Glu21.
Figure 3.25 shows the binding of dopamine to I113T SOD1 at the loop II groove and Table 
3.12 shows related crystallographic statistics. As expected there is good electron density 
around the catechol head group which makes typical hydrogen bonds with the Glu21 and 
Pro28 carbonyls,  the Glu100 carboxyl  and the loop II  ordered water  molecule (Figure 
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3.25C  and  Table  3.13).  Binding  is  replicated  with  slight  changes  in  conformation  in 
structures with other SOD1 variants and near physiological pH (Figure 3.26). While these 
bonds are conserved with respect to isoproteranol and dopamine, the hydroxyl hydrogen 
donor is switched in each case as the plane of the catechol group is rotated 180 o (Figure 
3.27).
Variant I113T I113T wild-type L38V H48Q
Resolution (Å) 1.00 1.90 1.89 1.53 1.55
Space group P21 C2221 P21 P21 P21
pH 5.0 8.0 5.0 5.0 5.0
Unit cell parameters:
a (Å) 38.4 165.4 38.6 38.6 38.7
b (Å) 68.0 203.4 68.2 67.1 67.9
c (Å) 49.9 144.6 50.9 52.3 50.5
α (o) 90.0 90.0 90.0 90.0 90.0
β (o) 104.8 90.0 105.8 106.7 105.7
γ (o) 90.0 90.0 90.0 90.0 90.0
Completeness (%) 96.8 (80.4) 97.0 (82.4) 92.9 (65.2) 99.8 (99.9) 99.8 (98.8)
Redundancy 3.7 (2.7) 7.0 (5.2) 2.7 (1.5) 3.6 (3.6) 3.6 (3.4)
R-merge (%) 4.7 (58.7) 11.3 (64.5) 9.9 (31.8) 16.7 (53.9) 8.0 (53.9)
I/σ 16.4 (1.6) 12.52 (1.62) 6.6 (2.0) 6.3 (2.2) 14.0 (2.1)
Rfact / Rfree (%) 15.8 / 18.2 20.0 / 23.2 23.9 (29.3) 29.8 / 34.3 19.9 / 23.7
RMS bond (Å) 0.015 0.016 0.016 0.015 0.015
Table 3.12. Single crystal X-ray diffraction data collection, processing and model refinement statistics for 
dopamine bound to SOD1.
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Figure 3.25. Dopamine bound to I113T SOD1. (A) Dopamine with respect to the SOD1 dimer in grey and 
light grey, strands 2, 3 and 6 of the SOD1 β-barrel are coloured yellow, purple and green respectively. (B) 
2Fo-Fc electron density map of dopamine contoured at 1σ at the Trp32 binding site with the SOD1 surface 
coloured by amino acid hydrophobicity and (C) hydrogen bonding between I113T SOD1 and dopamine 
shown with black dashed lines, a single water molecule is also shown as a red sphere.
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Figure 3.26. Dopamine bound to multiple SOD1 mutants. 2Fo-Fc electron density maps contoured at 1σ of the 
SOD1 loop II pocket with dopamine bound in (A) I113T SOD1 pH 8 C2221 crystal structure (B) L38V 
SOD1, (C) wild-type SOD1 and (D) H48Q SOD1 grown at pH 5 in the P21 form.
Donor I113T wtSOD1 L38V H48Q I113T pH8 Acceptor
Dopamine C1-OH 2.8 Å 2.7 Å 2.2 Å 2.9 Å 2.5 Å O=C-Pro28
Dopamine C1-OH 3.2 Å 3.0 Å 4.0 Å 3.4 Å 3.1 Å O=C-Glu21
Dopamine C1-OH 3.3 Å 3.4 Å 2.9 Å 3.3 Å 3.4 Å H2O
Dopamine C2-OH 2.6 Å 2.9 Å - 3.2 Å 2.5 Å COOH-Glu100
Dopamine C2-OH 3.3 Å 3.3 Å - 4.5 Å 3.4 Å O=C-Pro28
Table 3.13. Summary of potential hydrogen bonding interactions between SOD1 and dopamine in the loop II 
binding site.
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Figure  3.27.  Comparison  of  I113T  SOD1  structures  with  bound  catecholamines;  isoproteranol  (cyan),  
adrenaline (purple) and dopamine (orange).
The reason for this shift in orientation appears to be the lack of hydrogen bonding with the 
Glu21 carboxyl  through a tail  hydroxyl.  The dopamine tail  is  therefore untethered and 
projects into solvent away from Trp32. Electron density is, surprisingly, clearly defined for 
this part of the molecule (Figure 3.25B) possibly as a result of repulsion from Lys23 and 
Lys30 side chains.
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3.12 An in vitro assay to monitor SOD1 aggregation
While the etiology of SOD1 related fALS is currently ambiguous the disease manifests 
with  particular  phenotypic  characteristics.  Motor  neurone  cell  death  leading  to  a 
deterioration of muscle control, atrophy and ultimately death are the primary traits of all 
ALS sufferers. The knowledge that the SOD1 gene is mutated in a subset of cases 17 led to 
the observation that SOD1 protein accumulates as high molecular weight inclusions in the 
motor neurones of these individuals  68 and in mouse transgenic models  146.  In addition, 
fALS associated SOD1 mutant protein has been found to be destabilised and aggregation 
prone  in  vitro particularly when demetallated  and disulphide  reduced  78,86.  Banci  et  al 
observed that apo-I113T SOD1 undergoes a gradual but progressive disappearance of the 
dimeric form concomitant with evolution of higher molecular weight species when the 
protein was analysed by size exclusion chromatography after incubation at physiologically 
relevant concentration, pH and temperature 78. This work is recreated in Figure 3.28.
Figure 3.28. Aggregation of I113T SOD1 monitored by size exclusion chromatography. Apo-I113T SOD1 
(100 µM) in Tris-HCl 20 mM, NaCl 150 mM was incubated for the indicated time at 37 oC before 300 µl was 
was loaded onto a Superose 12 10/300 gel filtration column.
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Lansbury and co-workers have used this system to determine the effect of an intersubunit 
disulphide bond on A4V SOD1 aggregation  86 and the effect of putative SOD1 binding 
compounds  on  aggregation  130,131.  Indeed,  5-fluorouridine  and  isoproteranol  were  both 
assayed  for  aggregation  inhibition  by  quantifying  how  much  dimeric  apo-A4V SOD1 
remained after  incubation with the compound in comparison with an untreated protein 
control.  In  both  cases  more than 95 % of  A4V SOD1 was in  the dimeric  form when 
assayed. Although size exclusion chromatography is generally low though-put technique 
the small number of compounds presented in the previous sections allows their biological 
activity to be characterised using this methodology. The experimental conditions used in 
this study are explained below.
The intracellular concentration of SOD1 has been estimated to be in the low μM range 84. 
To fully represent this and in order to make valid comparisons with the work of Nowak et  
al 130 and  Banci  et  al 78 apo-SOD1 was  used  at  25  μM  and  100  μM concentrations 
thoughout. Physiological pH was maintained using Tris buffered saline and assays were 
incubated at 37 oC.
As can been seen in Figure 3.27, extensive dimer loss can be discerned after 48 hours. At 
this  time  point  a  large  peak  corresponding  to  high  molecular  weight  soluble  SOD1 
aggregates is also clearly visible. While a shorter time period (4 hours) was assessed in 
each  case,  the  extent  of  aggregation  after  such  a  short  incubation  time  prevented  an 
assessment of compound effectiveness. As a result, 48 hours was used throughout as the 
standard incubation period.
With no information concerning ligand binding affinities directly available from the crystal 
structure of a protein-ligand complex it is difficult to determine the concentration of ligand 
that should be used to measure its biological activity. Given that two of the compounds 
presented here have previously demonstrated aggregation inhibition activity at a 1:3 SOD1 
to ligand molar ratio 130, those conditions are replicated here. A 1:30 ratio is also presented 
in each case.
In order that ligands be allowed time to dock before the onset of aggregation a 15 minute 
incubation period with the ligand was effected before 5 mM EDTA was added to initiate 
66
aggregation.  This  is  fully  in  accordance  with  the  previous  work of  Lansbury  and co-
workers 130,131.
As described, adrenaline has limited solubility in aqueous buffers at neutral pH. Similarly, 
4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)quinazoline  (MPTQ)  has  very  limited 
solubility without the presence of DMSO. As a result neither of these compounds were 
assayed for aggregation inhibition.
In  the  previous  sections,  I113T SOD1 was  used  as  an  screening  test  case  for  ligand 
binding.  Banci et al used I113T SOD1 to demonstrate the inherently aggregation prone 
nature  of  SOD1 mutants  78. Figures  3.29 –  3.34 A and B show  in  vitro I113T SOD1 
aggregation in the presence of each of the compounds presented in the previous section 
under  the  conditions  described  above,  with  noted  exceptions,  as  monitored  by  size 
exclusion  chromatography.  These  experiments  were  repeated  with  each  SOD1 binding 
compound using L38V SOD1 (Figures 3.29 – 3.34 C and D).
The alanine to valine amino acid substitution at position 4 of the SOD1 polypeptide is the 
most common SOD1 mutant in North America and is widely regarded to manifest with the 
severest ALS phenotype  147. The A4V mutation is found at the SOD1 dimer interface  148 
and may exert its pathogenic effect by perturbation of the interface or distortion of the 
SOD1  β-barrel.  When  isoproteranol  and  5-fluorouridine  were  previously  analysed  for 
aggregation  inhibition  they  were  assayed  against  a  recombinant  A4V protein  130.  This 
protein was expressed in E. coli as a glutathione S-transferase fusion protein from which it 
was cleaved during protein purification  86. Cleavage occurs using a derivative of human 
rhinovirus 3C protease at the site Leu-Glu-Val-Leu-Phe-Gln-Gly-Pro between glutamate 
and glycine  149. Thus, removal of the fusion protein leaves the peptide Gly-Pro-Leu-Gly-
Ser N-terminal to the SOD1 primary alanine. Given over 50 % of SOD1 amino acids are 
found to have ALS related mutations and the N-terminus of SOD1 is found close to the 
dimerisation region it  is  conceivable that  addition of extra amino acids may effect the 
protein's  properties  particularly relating  to  its  aggregation  propensity.  In  order  to  fully 
characterise the compounds presented earlier and to act as a control for aggregation assays 
using I113T and L38V SOD1 an identical construct was cloned, expressed and purified 
according to published methodology 86. This SOD1 protein, with the A4V mutation and 5 
extra  N-terminal  amino  acids,  is  hereafter  termed  A4V+ SOD1.  The 6  SOD1 binding 
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compounds tested for aggregation inhibition with I113T and L38V SOD1 were examined 
in an identical fashion with apo-A4V+ SOD1 (E and F in Figures 3.29 – 3.34).
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Figure 3.29. Aggregation of recombinant SOD1 in the presence of MDTQ monitored by SEC. apoSOD1 at  
t=0 hrs is presented in each case (red) with apoSOD1 after 48 hrs incubation at 37 oC (green) compared with 
identical  samples containing 1:3 (blue) and 1:30 (cyan) concentrations of MDTQ. (A) I113T 25  μM (B) 
I113T 100 μM (C) L38V 25 μM (D) L38V100 μM (E) A4V+ 25 μM (F) A4V+ 100 μM.
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Figure 3.30 Aggregation of recombinant SOD1 in the presence of MPQ monitored by SEC. apoSOD1 at t=0 
hrs is presented in each case (red) with apoSOD1 after 48 hrs incubation at 37  oC (green) compared with 
identical samples containing 1:3 (blue) and 1:30 (cyan) concentrations of MPQ. (A) I113T 25 μM (B) I113T 
100 μM (C) L38V 25 μM (D) L38V100 μM (E) A4V+ 25 μM (F) A4V+ 100 μM.
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Figure 3.31 Aggregation of recombinant SOD1 in the presence of MDQ monitored by SEC. apoSOD1 at t=0 
hrs is presented in each case (red) with apoSOD1 after 48 hrs incubation at 37  oC (green) compared with 
identical samples containing 1:3 (blue) and 1:30 (cyan) concentrations of MDQ. (A) I113T 25 μM (B) I113T 
100 μM (C) L38V 25 μM (D) L38V100 μM (E) A4V+ 25 μM (F) A4V+ 100 μM.
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Figure  3.32  Aggregation  of  recombinant  SOD1  in  the  presence  of  5-fluorouridine  monitored  by  SEC. 
apoSOD1 at t=0 hrs is presented in each case (red) with apoSOD1 after 48 hrs incubation at 37 oC (green) 
compared with identical samples containing 1:3 (blue) and 1:30 (cyan) concentrations of 5-fluorouridine. (A) 
I113T 25 μM (B) I113T 100 μM (C) L38V 25 μM (D) L38V100 μM (E) A4V+ 25 μM (F) A4V+ 100 μM.
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Figure 3.33 Aggregation of recombinant SOD1 in the presence of isoproteranol monitored by SEC. apoSOD1 
at t=0 hrs is presented in each case (red) with apoSOD1 after 48 hrs incubation at 37 oC (green) compared 
with identical samples containing 1:3 (blue) and 1:30 (cyan) concentrations of isoproteranol. (A) I113T 25 
μM (B) I113T 100 μM (C) L38V 25 μM (D) L38V100 μM (E) A4V+ 25 μM (F) A4V+ 100 μM.
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Figure 3.34 Aggregation of recombinant SOD1 in the presence of dopamine monitored by SEC. apoSOD1 at  
t=0 hrs is presented in each case (red) with apoSOD1 after 48 hrs incubation at 37 oC (green) compared with 
identical samples containing 1:3 (blue) and 1:30 (cyan) concentrations of dopamine. (A) I113T 25 μM (B) 
I113T 100 μM (C) L38V 25 μM (D) L38V100 μM (E) A4V+ 25 μM (F) A4V+ 100 μM.
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When apo-SOD1 is  analysed by SEC a single peak corresponding to the apo dimer is 
observed (Figures 3.29 – 3.34 red lines). Following incubation at 37 oC the height and area 
of this peak is reduced corresponding to the SOD1 dimer moving into higher molecular 
weight oligomers (Figures 3.29 – 3.34 green lines). In the case of the three quinazolene 
derivatives tested here, I113T, L38V and A4V+ SOD1 aggregation is not inhibited  by 
addition of  a 1:3 and 1:30  molar ratio (Figures 3.29 – 3.31). This is demonstrated by the 
similar dimer peak heights when comparing the apo-SOD1 control after 48 hours and those 
of containing compound. In most cases there is a slight decrease in dimer prevalence at 
high compound concentration.
Neither  isoproteranol,  5-fluorouridine  or  dopamine  (3.32  -  3.34)  exhibit  any  SOD1 
aggregation inhibition as determined by observation of the SOD1 dimer peak height and 
area. Figures 3.33 and 3.34 both exhibit strong absorbance in the 7 – 13 ml region when 
high catecholamine concentrations are used seemingly indicating an vast increase in the 
prevalence of high molecular weight SOD1 species. This is likely an artefact of strong UV 
absorption  by  catecholamine  oxidation  products  but  indicates  the  presence  of  the 
compound  in  higher  molecular  weight  species.  These  species  must  be  either  SOD1-
compound complexes or compound-compound complexes.
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Chapter IV
Discussion of small molecule SOD1 binding and the effect upon 
SOD1 aggregation in vitro
4.1 The SOD1 screening pipeline
Appendix  IV  illustrates  the  43  compounds  screened  here  for  SOD1  binding  using  a 
crystallographic  approach.  Including  the  Rigaku  ActiveSite  library  this  amounts  to 
approximately 450 compounds.  This throughput  would not  have been possible  without 
efficient protein expression and reliable protein crystallisation. The system implemented 
here allows compounds to be tested against SOD1 proteins which belong to each of the 
major  SOD1  mutation  groups;  dimer  interface,  copper  site,  loop  and  the  wild-type 
prototype.
4.2 The SOD1 tryptophan-32 binding site
4-(4-methyl-1,4-diazepan-1-yl)-2-(trifluoromethyl)quinazoline  (MDTQ)  is  patented  as  a 
modulator of ALS. This compound was found to bind to G93A SOD1 at a site over Trp32 
with its trifluoromethyl moiety embedded in a cavity created by Val31, Ser98 and Glu100 
123. Here the binding of MDTQ at this site has been confirmed by single crystal X-ray 
diffraction structure determination and found to occur in a variety of SOD1 mutants as well 
as the wild-type form.
Figure 4.1. The structures of four SOD1 binding quinazoline derivatives.
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Figure 4.1 shows the four quinazoline bases compounds found to bind SOD1 during the 
course  of  this  study.  Modification  of  two  of  the  groups  substituted  on  the  central 
quinazoline ring of MDTQ had disparate effects on its interaction with SOD1. Removal of 
a  carbon  from  the  homopiperazine  group  to  form  4-(4-methylpiperazin-1-yl)-2-
(trifluoromethyl)quinazoline (MPTQ) severely affected the compound's solubility, limiting 
its availability in soaking experiments, but did not change its mode of binding. Removal of 
the  trifluoromethyl group on C2 to form 4-(4-methylpiperazin-1-yl)quinazoline (MPQ) or 
4-(4-methyl-1,4-diazepan-1-yl)quinazoline  (MDQ)  prevents  formation  of  3  hydrogen 
bonds between this group and the protein. As can been seen in Figures 3.6 and 3.9, in both 
cases the quinazoline ring system slightly shifts position away from Ser98 perhaps in order 
to maximise the hydrophobic interaction with the Trp32 indole. This prevents formation of 
the Ser98-quinazoline N1 hydrogen bond. It seems reasonable that ablation of these bonds 
will weaken the overall interaction between ligand and protein.
Analysis  of SOD1 protein aggregation in the presence of these quinazoline derivatives 
indicated no obvious effect when compared to a control. Similarly, 5-fluorouridine was 
also found to bind at the Trp32 site and form hydrogen bonds with Lys30 and Ser98. This 
compound also had no effect on SOD1 dimer loss.
4.3 The SOD1 loop II binding site
Figure 4.2 shows the structure of the three catecholamine compounds found here to bind at 
a site in the groove created by amino acids Glu21 – Trp32 at the loop II region of the 
SOD1 β-barrel.
Figure 4.2. The structures of three SOD1 binding catecholamines.
Each of  these  compounds is  capable  of  making several  hydrogen bonding interactions 
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between the catechol head group and SOD1. One ordered water that sits in loop II is also 
important in this  regard.  Interactions between the tail  amine and hydroxyl  groups with 
Glu21 appear to dictate the conformation of the catechol head group as described in Figure 
3.26. Dopamine does not make hydrogen bonds between tail and Glu21 indicating that its 
affinity  for  the  loop  II  site  will  be  reduced  in  comparison  with  isoproteranol  and 
adrenaline.
When isoproteranol and dopamine are assayed for their effect on SOD1 aggregation we 
find that both compounds seem to promote formation of high molecular weight species as 
determined by the increased 280nm absorption at high compound concentrations in the 7 – 
13  ml  region  of  their  respective  SEC  traces.  Dopamine  shows  extraordinarily  high 
absorption  in  this  region  possibly  arising  from  the  non-specific  effects  of  dopamine 
toxicity mediated by its oxidation products dopa-quinone and indolequinones or formation 
of melanin 150.
4.4 Lansbury compounds and contrary results
The course which leads from SOD1 mutation to motor neurone cell death and ALS is not  
clearly delineated. This is despite the best efforts of many people over the course of nearly 
two decades since its first implication as causative factor in ALS. SOD1 aggregation and 
the resulting disruption of cellular process is heavily implicated in disease pathogenesis 
however  as  it  is  the  only  indisputable  and  unifying  cell  level  disease  characteristic 
preceding cell death. SOD1 polymerisation resulting from a monomerisation event leading 
to aggregation prone monomers has been proposed as the pathogenic mechanism 151.
This concept takes a lead from observation of mutant transthyretin (TTR) behaviour in the 
neurodegenerative disease familial amyloid polyneuropathy (FAP) 152. This disease initiates 
with dissociation of tetrameric TTR followed by conformational changes to the monomer 
and aggregation of these modified monomers into fibrillar oligomers  153. Small molecule 
inhibition of TTR tetramer dissociation has been shown to reduce aggregates in vitro and in 
patient trials 154.
Isoproteranol and 5-fluorouridine were identified through an in silico screen for molecules 
targeting  the  SOD1  dimer  interface  pocket  created  by  amino  acids  Val7,  Gly146  and 
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Val147  130.  These molecules  aimed to inhibit  SOD1 monomerisation by replicating the 
effect  of  an  artificial  intersubunit  disulphide  bond  created  by the  mutation  V148C  86. 
Validation  of  their  effect  was  monitored  by  observing  the  quantity  of  dimeric  SOD1 
remaining after a period of time  130. Here we find that isoproteranol and 5-fluorouridine 
bind at sites proximal but distinct in the loop II region on the surface of the SOD1 β-barrel. 
This  area  is  distant  from  the  dimerisation  region  and  the  result  questions  the 
monomerisation hypothesis as the cause of SOD1 aggregation. If both compounds exert a 
protective  effect  on  dimeric  SOD1  as  published  by  Nowak  et  al 130 and,  as  neither 
compound induces large conformational changes, that effect must exert itself at the site, or 
close to the site, at which the compound binds. As a result the protective effect is likely an 
inhibition of non-native dimer contacts that take place in the loop II region rather than 
inhibition  of  monomerisation  that  ultimately  leads  to  polymerisation.  This  strongly 
implicates the loop II region in SOD1 mediated fALS pathogenicity.
4.5 Loop II and Trp32 in SOD1 pathology and implications
The Trp32-loop II region of SOD1 (Figure 4.3) has previously been found to form one of 
three  crucial  determinants  of  SOD1  aggregation  in  vitro 155.  This  is  corroborated  by 
analysis  of the SOD1 primary sequence using tools designed to predict  regions with a 
propensity for aberrant multimerisation 156.
Figure 4.3. The SOD1 dimer (2C9V). β-strand 2 and 3 are highlighted turquoise and purple respectively and 
loop II in blue. SOD1 Trp32 is also shown in purple.
The single SOD1 tryptophan is unusually solvent exposed on the surface of the SOD1 β-
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barrel. Zhang et al noted in 2003 that bicarbonate was able to induce covalent aggregation 
of wild-type SOD1 by tryptophan oxidation  157.  Using  β-strand 3 peptide mimetics this 
group was able to determine that SOD1 Trp32 could be modified to hydroxytryptophan, 
kynurenine and N-formylkynurenine  158. This was followed by observations on wild-type 
human  SOD1  isolated  from  erythrocytes  confirming  that  oxidatively  modified  SOD1 
comprises 20 – 30 % of the total cellular pool and that Trp32 in particular can be modified 
by the addition of one or two oxygen atoms 159.
These findings are novel with respect to SOD1 biology but become especially interesting 
in light of experiments using a W32F SOD1 mutant. This amino acid substitution prevents 
the formation of covalently bonded SOD1 aggregates  in vitro 157 and prolongs the life 
expectancy  of  spinal  cord-dorsal  root  ganglia  cell  cultures.  In  the  latter  case,  cells 
transfected with a G93A/W32F double mutant expression plasmid had comparable life 
expectancies with those expressing wild-type SOD1 driven by the same system and almost 
twice that of those expressing a G93A single mutant 159. These results are corroborated by 
recent  findings  that  fALS  associated  SOD1  mutants  are  unable  to  propagate  SOD1 
misfolding in mouse transgenic models when expressed as a double mutant with W32S 160.
4.6 Affinity & NMR experiments
Affinity, efficiency, efficacy and specificity are of critical importance alongside ADMET 
properties  in  any drug development  pipeline  from initial  hit  through optimisation  to  a 
compound  that  could  be  a  candidate  for  clinical  trials.  One  method  to  ensure  that 
successive iterations of a compound are changing the compounds characteristics in the 
desired way is to measure the strength of ligand binding. The change in free entropy (ΔS) 
and enthalpy (ΔH) on ligand binding are often used as a measure of affinity 161. During the 
course of this work each of the compounds presented as binding to SOD1 were analysed 
by isothermal titration calorimetry and, in the case of isoproteranol, one-dimensional NMR 
spectroscopy. Despite good electron density in the crystal structures, high quality protein 
samples and highly pure ligand no data regarding the affinity of any of these compounds 
could be gleaned.
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4.7 Prospects and further work
The catecholamine and quinazoline compounds presented here represent excellent initial 
scaffolds upon which groups can be added in order to increase specificity and affinity. 
Each of the compounds presented has a molecular weight below 310 gMol -1 and could be 
reduced even further to those groups which appear critical to binding. The catechol head 
group and the trifluoromethyl attached to a planar aromatic moiety are the groups which 
appear to make the most contacts with the peptide. Their binding site proximity together 
with the disease importance attached to this region encourages the notion of a chimeric or 
linked  compound  to  take  advantage  of  both  sites.  Fragment  linking  is  not  without 
difficulties  however,  due  to  the  reduction  of  rotational  freedom  encountered  during 
fragment binding often the binding affinities of linked compounds are not of the expected 
strength 162.
A key factor in the growth of these compounds into SOD1 therapeutics is development of 
an assay to determine their biological effect. The SEC aggregation assay deployed in this 
work has previously been used with respect to SOD1 however the contradictory results 
obtained  here question both the results and the assay. A cell model for SOD1 toxicity has 
been developed and has been used in targeted drug development  163, as have transgenic 
mouse models  164. While these are more expensive and each has limitations in terms of 
throughput they are undoubtedly a better representation ALS neurones.
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Chapter V
An introduction to the human copper chaperone for SOD1 and 
small-angle X-ray scattering
5.1 Copper metabolism
The evolutionary shift to aerobic respiration resulted in the need for organisms to utilise an 
element with high redox potential. As the atmosphere became more oxidising this demand 
could not be filled by iron, which was converted into the insoluble iron (III) form. It could 
be fulfilled by the newly bioavailable copper which was well suited to the task  165. As a 
result of this change and the subsequent proliferation and evolution of aerobic organisms, 
copper became an essential element for the vast majority of species 166. In humans copper 
is an essential cofactor of enzymes involved in respiration, iron transport and free radical 
scavenging among others.
While copper's redox properties are a solution to one set of problems it is also the cause of 
another set. Free soluble copper is a source of oxidative stress because it generates reactive 
oxygen species through Fenton chemistry  167. Consequently, the intracellular free copper 
concentration must be kept at a minimum. It is known to be ~10 -18 M in yeast cells which 
equates to less than one free copper atom per cell 168. Under these circumstances it is very 
unlikely that a newly synthesised copper binding protein will  find an amenable copper 
cofactor.
5.2 The membrane bound copper transporter and metallochaperones
The metallochaperones are a group of soluble intracellular proteins that are responsible for 
the chelation and movement of metal ions from their  entry into the cell  to their  target 
protein  169.  Copper  metallochaperones  are  involved  in  three  pathways  i)  secretory/iron 
uptake, ii) activation of cytochrome c oxidase and iii) activation of SOD1. Each pathway 
begins with copper uptake by one of the copper transporter family (Ctr); in humans this is 
hCTR1 170. Copper then passes along an increasing affinity gradient that prevents binding 
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by  cytoplasmic  low  molecular  weight  metal  chelators  such  as  metallothionine  and 
glutathione 171.
Copper  transport  by  human  CTR1  is  inhibited  by  silver  but  not  divalent  metal  ions 
indicating that Cu(I) is the substrate 172. hCTR1 is an integral membrane protein and forms 
a homotrimer with a central pore 173. Each monomer has an extracellular N-terminus and an 
cytoplasmic C-terminus 174. This cytoplasmic region is known to exchange Cu(I) with the 
S. cerevisiae  cytoplasmic, secretory pathway metallochaperone Atx1  175.  This protein in 
turn  delivers  Cu(I)  to  the  Atx1-like  domain  of  the  membrane bound secretory vesicle 
protein Ccc2  176,177. In an analogous system, reliant on Cox17, copper is delivered to the 
intermembrane  space  of  the  mitochondria  where  it  is  shuttled  along  inner  membrane 
proteins before transfer to cytochrome c oxidase 178.
amino acid similarity: identical Strong Weak Not matching
Conserved copper binding cysteine Intramolecular disulphide bond cysteine
SOD1 metal binding ligands
Figure 5.1. Multiple protein sequence alignment CCS and SOD1 proteins. S. cerevisiae Atx1 (GI:1255959), 
yCCS/LYS7 (GI:729967), hCCS (GI:49456811), hSOD1 (GI:49456443) and ySOD1 (GI:1015812) generated 
using BLOSUM 179.
Human SOD1 is found in the cytoplasm and the mitochondrial intermembrane space 46,180. 
In each of these locations Copper Chaperone for SOD1 (hCCS) interacts  directly with 
SOD1 and can load copper into the nascent protein 181-183. hCCS was first discovered as a 
homolog of a yeast protein (Lys7/yCCS) that specifically delivered copper to yeast SOD1, 
indeed, hCCS is 26% identical to yeast yCCS (Figure 5.1) and displays similar domain 
architecture 182.
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5.3 Domain architecture of hCCS
Domain I of both hCCS (residues 1 - 80) and yCCS shows considerable homology to the 
S.  cerevisiae Atx1 protein  (Figure  5.2A).  This  region contains  a  conserved MXCXXC 
motif seen at the N-terminal region of several copper transport proteins  184-186. This motif 
has been shown to bind Cu(I)  187,188 and other metal ions  189,190. Removal of this domain 
from the yCCS protein does not eliminate its activity as a domain II/III truncation protein 
could  effectively  complement  a  LYS7Δ  strain  191.  However,  under  copper  limited 
conditions domain I is essential for LYS7Δ complementation 191. Conversely, domain I was 
proved  essential  for  human  CCS  functioning  with  deletion  of  this  domain  ablating 
activation of SOD1 in vivo in embryonic fibroblasts 192.
Figure 5.2. Structures of the three hCCS domains. (A) NMR structure of the Atx-1 like domain I (2CRL), (B)  
crystal structure of SOD1-like domain II monomer (1DO5) and (C) the predicted structure of domain III. 
Copper-binding regions are indicated in red. Taken from Wright et al 193.
Domain II (residues 85 - 234) exhibits 50% identity to wild-type hSOD1 (Figure 5.2B). 
Similarity  between  these  proteins  extends  to  the  catalytic  copper  and  structural  zinc 
binding sites of SOD1 (Figure 5.1, purple residues). The metal coordinating amino acids 
are intact in hCCS except for the residue corresponding to histidine 120 which is replaced 
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by aspartic acid. The reverse mutation at this site bestows superoxide scavenging activity 
on yeast CCS but the native protein is not functional as a dismutase 194. This arrangement 
proposes a copper binding site in CCS similar to that of SOD1 and seems to be an obvious 
protagonist in the transfer of copper to its destination. However, these residues were not 
required for SOD1 activation when tested in the yeast system 191. Crystallographic studies 
on hCCS domain II found that this pseudo-copper site was not occupied but the zinc site 
was occupied 195. The presence of zinc in the SOD1-like site was subsequently confirmed 
by EXAFS 196.
hCCS domain II also houses two cysteine residues that align with those involved in the 
SOD1 intramolecular disulphide bond (Figure 5.1, green residues). This disulphide bond is 
present in the crystal structure and anchors strand eight of the β-barrel to the disulphide 
loop as in SOD1 195.
Domain  III  (residues  235  –  274,  Figure  5.2C)  is  very  highly  conserved  among  CCS 
proteins  from different  species  and was  proven  essential  for  yCCS function  under  all 
conditions  191.  It contains a CXC motif  that binds Cu(I) and is essential for transfer of 
copper to SOD1 191. Based on XAS data and recombinant CCS copper content, Eisses et al 
proposed this motif could interact with the MXCXXC of domain I or another domain III 
from a  CCS homodimer  partner  197.  These  interactions  are  likely to  occur  under  non-
limiting copper conditions via a di-, tri-, or tetra-nuclear copper cluster 196.
Equally  important  for  the  maturation  of  SOD1  is  the  oxidation  of  its  intramolecular 
disulphide bond 75. While formation of this bond can be catalysed by oxygen 80 and reduced 
glutathione  82, CCS is the primary catalyst for most organisms and is the only system in 
yeast 80,198. Crystallisation of a ySOD1 H48F mutant in heterodimeric complex with yCCS 
revealed a disulphide bond between ySOD1 Cys57 and yCCS domain III Cys229 199. This 
finding demonstrates a possible mechanism by which SOD1 acquires an intramolecular 
disulphide bond concomitantly with copper loading.
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Figure 5.3. The accepted mechanism of SOD1 copper loading by hCCS.
To summarise, hCCS appears to contain one zinc ion in domain II at the SOD1 analogous 
site.  The  domain  II  copper  site  is  not  necessary  for  function  and  is  not  necessarily 
occupied.  Figure  5.3  describes  the  function  of  hCCS  in  SOD1  activation.  Domain  I 
sequesters copper  from the environment or CtrI  and passes it  to domain III.  A hetero-
complex is  formed through an interaction between CCS domain II  and SOD1. Copper 
loaded domain III then forms an intermolecular disulphide bond with SOD1 Cys57 and 
transfers  copper  to  the  SOD1 active  site.  Subsequent  reorganisation  of  this  disulphide 
creates the SOD1 internal disulphide and enables separation of the hetero-complex.
5.4 X-ray scattering
X-ray scattering and X-ray crystallography are related techniques that exploit the elastic 
scattering of X-rays by electrons in matter. Both rely on measurement of the intensity and 
angle of deflection of X-rays scattered by the sample. The fundamental difference is the 
nature of the substance under investigation. Crystallography utilises the periodicity of the 
crystalline lattice and the superposition property of electromagnetic  radiation to  enable 
atomic level characterisation of the sample. X-ray scattering on the other hand measures 
isotropic scattering and does not require the sample to be crystalline. In fact scattering can 
be performed on any non-crystalline material including liquids, gasses, amorphous solid 
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and, most importantly for protein characterisation, molecules in solution 200.
5.5 X-ray scattering by biological macromolecules in solution
Protein  in  solution  is  of  primary  interest  to  the  structural  biologist  and  although  the 
principles of X-ray scattering hold regardless of the state of the sample what follows is 
concerned  with  small  angle  X-ray  scattering  (SAXS)  from  protein  solutions.  In  a 
sufficiently large volume and concentration of such a solution all orientations of the solute 
molecule are present simultaneously. Thus scattering occurs radially around the beam and 
is  equivalent  to  the  scattering  from  a  single  particle  averaged  over  all  orientations 
according to the Debye equation 201
I (q)=∫∫
V
ρ(r 1)ρ(r2)
sin qr 12
qr12
dr1 dr 2
where r12 describes the spatial distance between scattering atoms ρ(r1) and ρ(r2) in volume 
V with q, momentum transfer, given by the equation
q=4π sinθ
λ
where, λ is wavelength and θ is half the angle between the incident and scattered radiation. 
The highest intensity (I)q is found parallel to the incident beam (2θ = 0) and decreases as 
2θ increases. A characteristic scattering profile is obtained by subtracting scattering by the 
buffer from that of the protein solution and plotting intensity against momentum transfer. 
The lowest angle part of this curve is dictated by the radius of gyration, R(g) which is the 
root  mean  squared  distance  of  each  scatterer  from  the  molecule's  centre.  At  low  q, 
scattering can be approximated by the Guinier approximation 202
I (q)= I (0)exp
(−q2 Rg
2)
3
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Thus R(g) can be calculated by
R(g )=√−3m
where m is the gradient of the Guinier plot, I(q) vs q2. Linearity of the Guinier region gives 
a good indication of sample monodispersity.
A Fourier transform of the scattering profile gives the pair distance distribution function, 
p(r). The p(r) function is given by
p (r )= 1
2π2
∫
0
∞
I (q)qr sin (qr )dq
and describes the frequency of intra-atomic lengths and the scattering particle's maximum 
linear dimension  202,  Dmax.  A plot of this function is useful when appraising the overall 
shape and anisometry of a molecule.
5.6 Ab initio shape restoration from the scattering curve
While precise atomic co-ordinates cannot be gleaned from SAXS data, a representative 
three dimensional molecular envelope can be constructed from a scattering profile without 
previous knowledge of protein structure. Several algorithms have been developed for  ab 
initio shape restoration. The most widely used of these generate models using beads to fill 
a volume defined by the deduced scattering parameters in a way that produces a scattering 
profile which approaches that obtained experimentally. An inherent flaw in this approach is 
that many diverse models can be generated that  fit  the experimental data.  This can be 
overcome to some extent by repetition of the method and averaging the pool of structures.
GASBOR, the shape restoration algorithm exploited in the following chapters creates a 
three dimensional  model  by finding a chain-compatible  spatial  arrangement  of dummy 
residues that fits the scattering profile up to 0.5 Å-1 203. Dummy residues are centred on 
hypothetical Cα atoms and must  be at  most  3.8 Å from its  nearest  neighbour ensuring 
compactness and connectivity. A final model is condensed from a spherical assembly of 
dummy residues by a cyclic simulated annealing protocol until further optimisation does 
88
not change a goal function which incorporates the described constraints.
5.7 Rigid body modelling
A SAXS model can be thought of as a low resolution envelope in which one can fit high 
resolution structures. For proteins with multiple domains connected by flexible linkers or 
subunits this is the aim of rigid body modelling against SAXS data and can provide more 
detailed information than space filling ab initio models solely. As with ab initio methods, 
rigid  body  modelling  attempts  to  minimise  the  difference  between  experimental  and 
theoretical  scattering  by  changing  the  relative  orientations  of  domains.  If  steric  and 
electrostatic restraints are applied to limit translation and rotational domain shifts, models 
can be generated which represent conformational variations of these mobile domains thus 
indicating possible dynamic features.
Here the programs BUNCH and CORAL 204 have been used to fit known domain structures 
against  experimentally  obtained  scattering  profiles.  These  programs  model  full-length 
proteins as rigid domains linked by flexible chains of dummy Cα atoms 204. Each rotation or 
translation of a domain changes its scattering amplitude so that the scattering intensity, I(q) 
of the complex is given by 
I (q)=〈∣∑k=1K A(k)(q)∣
(2)〉Ω
where  A(k)(q)  is  the  scattering  amplitude  of  the  kth rigid  body and  <  >Ω accounts  for 
spherical  averaging in reciprocal space. Each model is assessed for its goodness of fit to 
the experimental intensity, Iexp(q) by the magnitude of
χ2= 1
N−1∑j [ I exp(q j)−cI (q j)σ(q j) ]
2
where  σ(qj)  is  the  experimental  error  at  momentum transfer  (qj),  N is  the  number  of 
experimental points and c is a scaling factor.
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5.8 Summary
While the yeast CCS homolog has been characterised structurally and biochemically hCCS 
is  still  relatively unknown. Structural information regarding this  protein is  limited to a 
2.75Å resolution crystal structure of the central SOD1-like domain 195 and a NMR structure 
of  domain  I  deposited  in  the  Protein  Data  Bank  by  the  RIKEN  structural  genomics 
initiative.  Full  length  hCCS has  never  been  directly  observed  and  the  conformational 
dynamics of this entire class of proteins are completely uncharacterised. Similarly, details 
of  the  interaction  between hSOD1 and hCCS are  sparse.  The two successive  chapters 
describe the cloning, expression and purification of recombinant hCCS from an  E. coli 
host.  This  is  followed  by characterisation  of  hCCS  in  solution  by  small  angle  X-ray 
scattering. Finally the functionally crucial heterodimeric complex formed by hCCS and 
SOD1 is characterised using SAXS and the implications of this work are discussed.
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Chapter VI 
Solution X-ray scattering studies on hCCS and SOD1
6.1 Expression of recombinant hCCS in Escherichia coli and purification
DNA coding for wild-type human CCS was amplified from an EST clone and inserted, 
using a ligation dependent cloning approach, into the pET-24d derived plasmid pETM-11 
to yield the expression plasmid pETM11-hCCS. Expression from this plasmid is driven by 
T7 RNA polymerase on induction with a suitable inducer  205. Recombinant human CCS 
expressed as described is fused with a hexa-histidine tag that facilitates purification of the 
protein by nickel affinity chromatography 206.
Expression of recombinant protein from the pETM-11 vector incorporates the amino acid 
sequence Glu-Asn-Leu-Tyr-Phe-Gln-Gly-Ala prior to its N-terminus. This sequence is the 
target site for TEV (tobacco etch virus) protease  207 and can be used to remove the extra 
amino acids which form the protein's poly-histidine tag. Cleavage takes place between the 
Gln-Gly  residues  leaving  glycine  and  alanine  N-terminal  to  the  primary  methionine. 
Recombinant hCCS can then be purified to homogeneity by removal  of the free poly-
histidine  tag  and 6His-TEV protease from the  solution  by reapplication  to  the  NiNTA 
column (Figure 6.1).
Figure 6.1. Purification of recombinant hCCS. (A) SDS-PAGE separation of fractions from the purification 
of polyhistidine tagged hCCS by nickel affinity chromatography. (B) SDS-PAGE separation of samples from 
the digestion of 6His-hCCS by TEV protease followed by reverse purification on a NiNTA column. Digestion 
was performed on ~50mg 6His-hCCS at 4oC with 100μg/ml TEV protease overnight. SDS-PAGE separation 
in both cases was performed with 12% resolving-4% stacking Tris-glycine protein gels and stained with 
coomassie stain.
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Purification of hCCS by this method yields ~90 mg/l of liquid culture and the protein can 
be concentrated over 25 mg/ml. The protein has a molecular mass of 29.168 kDa (Figure 
6.2)  which compares very well with the predicted peptide molecular mass of 29.1687 kDa. 
It  contains  a  stoichiometric  amount  of  zinc  but  negligible  copper  as  determined  by 
electrospray ionisation mass spectroscopy (ESI-MS) and inductively coupled plasma mass 
spectrometry  (ICP-MS)  respectively.  When  the  protein  is  examined  by  size  exclusion 
chromatography a dominant peak at ~60 kDa is observed indicating that hCCS produced in 
this  way  is  predominantly  dimeric  (Figure  6.3).  However  tetrameric  protein  is  also 
observed, as previously described by Winkler et al 208 and Rae et al 209.
Figure 6.2. Electrospray ionisation mass spectrometry of recombinant hCCS.
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Figure  6.3.  Size  exclusion  chromatography  profile  of  recombinant  hCCS.  Fractions  from  NiNTA 
chromatography suspected to contain hCCS were pooled, concentrated to 2 ml, loaded and separated on a  
calibrated Superdex 200 16/60 gel filtration column with an ÄKTA purifier with flow rate of 1 ml/min at 20 
oC under reducing conditions. The column was calibrated (grey) with A - aldolase 158 kDa (65.5 ml), B – 
bovine serum albumin 67 kDa (73.5 ml) and C - ovalbumin 43 kDa (80.5 ml). A characteristic peak at ~74 ml 
is observed corresponding to the hCCS dimer (black).
The structure of the apo-hCCS domain I, deposited in the Protein Data Bank by the RIKEN 
structural genomics initiative (PDB ID: 2CRL), shows no sign of oligomerisation. This 
rules out domain I as the possible dimerisation site when it is in the copper-apo form. The 
yeast CCS homolog is known to form a dimer through the interaction of its SOD1-like 
domains  210.  Similarly,  hCCS truncated to comprise only domain II  exhibited a similar 
domain interface in the crystal structure to that of SOD1 195. We can infer therefore that full 
length hCCS in the copper depleted state forms a dimer with domain II as the interface. 
This point is important to emphasise as the following sections deals with the interpretation 
of small angle scattering data where dimerisation through domain II was imposed while 
modelling hCCS in solution.
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6.2 hCCS small angle X-ray scattering and assignment of scattering parameters
Scattering experiments were performed on the SWING beamline at Synchrotron SOLEIL, 
Paris. This beamline incorporates an online size exclusion chromatography HPLC system 
for the separation of proteins immediately prior to exposure to the X-ray beam  211. This 
synthesis of techniques eliminates the contribution of higher or lower molecular weight 
species from the scattering profile of the species under investigation. This was deemed 
especially important for hCCS as tetrameric protein exists in solution and large molecular 
weight  aggregates  form  spontaneously.  These  species  would  disproportionally  affect 
deduced scattering parameters as the intensity of scattering is proportional to the square of 
the total number of electrons which constitute the scatterer.
The  apparatus  allows  the  user  to  take  numerous  exposures  over  the  course  of  protein 
elution.  Initial  analysis  of  the  hCCS elution  profile  described in  terms  of  the  forward 
scattering  intensity,  I(0),  which  is  directly  related  to  the  concentration  and  molecular 
weight of the protein, indicates a major peak corresponding to the hCCS dimer preceded 
by that of the tetramer (Figure 6.4). The radius of gyration,  R(g), attains a steady value 
over  the  dimer  peak  but  increases  sharply  moving  toward  the  tetramer  and  higher 
molecular  weights.  This  graph  confirms  the  suspicion  that  SAXS measurement  of  the 
hCCS dimer in bulk solution is impractical due to the contribution from these species. 
Deduced SAXS parameters would be an average of every species in the heterogeneous 
sample. Using this graph one can estimate the R(g) of dimeric and tetrameric hCCS to be 
approximately 30 Å and 40 Å respectively.
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Figure 6.4. Size exclusion chromatography profile of hCCS described by radius of gyration and forward 
scattering intensity,  R(g) and  I(0). Frames 168 – 175 were averaged and used for the subsequent analysis. 
Adapted from Wright et al 193.
A region of this elution profile over the hCCS dimer peak with steady  R(g) values was 
averaged.  The  resulting  single  scattering  profile  is  shown  in  Figure  6.5.  Further 
manipulation  of  this  data  yields  the  Guinier  plot  in  Figure  6.6,  distance  distribution 
function Figure 6.7 and Kratky plot Figure 6.8.
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Figure 6.5. Solution X-ray scattering profile of hCCS. Experimentally obtained scattering curve with errors is 
in black while the smoothed scattering profile obtained by back-transform of the p(r) (Figure 6.7) is cyan.
Figure  6.6.  Guinier  plot  of  X-ray  scattering  from  hCCS.  Data  points  (4  -  30)  used  in  the  Guinier 
approximation are highlighted cyan.
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Figure 6.7. hCCS distance distribution function, p(r). Errors are increased by a factor of 10.
Figure 6.8. hCCS Kratky plot.
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Figure  6.6  shows the  Guinier  plot  of  the  hCCS scattering  profile  at  very low  q.  The 
calculated radius of gyration R(g), related to the gradient of the linear part of the plot by 
the  Guinier  approximation,  is  30.5  ±  0.3  Å.  This  equates  well  with  the  R(g)  value, 
calculated from the  p(r)  function (Figure 6.7), of 31.5 ± 0.3 Å. The maximum particle 
dimension, Dmax, given by the intercept of the p(r) function with the x axis is 118 ± 5 Å. 
The asymmetric shape of the p(r) function, with Dmax/2 significantly larger than the peak 
maximum is indicative of an elongated molecule. A Kratky plot is a useful measure of the 
compactness of a protein. A folded protein will produce a bell-shaped plot at low angles 
that  approaches  the  abscissa  at  high  q values.  Conversely a  non-compact  or  unfolded 
protein will remain high after the initial maximum. Figure 6.8 shows the Kratky plot for 
hCCS and demonstrates  the  largely folded nature  of  hCCS as  the  trace  returns  to  the 
baseline after the primary peak.
6.3 Ab initio shape reconstruction
The  scattering  data  described  in  the  previous  section  was  used  to  construct  a  three-
dimensional model of the hCCS dimer using the  ab initio shape reconstruction program 
GASBOR. This program finds an arrangement of residues that best describes the scattering 
pattern of the studied protein starting from a random collection of residues approximated 
by spheres 203. Initial model building attempts using a two-fold symmetry axis resulted in 
higher than anticipated goodness of fit values (2.54<χ2<3.39) for the generated structures. 
When  symmetry  was  not  imposed  on  model  building  these  values  were  consistently 
improved  (1.90<χ2<3.14).  This  indicates  there  is  little  symmetry  between  the  two 
monomers  that  comprise  the  hCCS dimer  and  domain  I  and  III  appear  to  be  largely 
independent with respect to their counterparts in the other monomer. Using GASBOR, 20 
models were constructed and the structure found to be the most typical (Figure 6.9) was 
then used as the reference for averaging. Of the 20 models (Figure 6.10), one was rejected 
from the averaging process on the basis that it showed dissimilar shape compared to others 
in the cohort.
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Figure 6.9. Ab initio P1 shape reconstruction of hCCS. (A) A single reconstruction is depicted rotating 360o 
along its long axis, χ2 = 1.9. (B) The computed profile of the reconstruction with the hCCS experimental 
scattering for comparison.
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Figure 6.10. 18  ab initio P1 shape reconstructions of hCCS. The models presented have goodness-of-fit 
values 1.9<χ2< 3.1.
Figure 6.11. Consensus shape of all  ab initio non-symmetrical SAXS models of hCCS. For comparison a 
ribbon model of the crystal structure of hCCS domain II (blue, PDB: 1DO5), which closely resembles the  
SOD1 dimer is superimposed on the average 3D shape model (red). The model is shown moving through a 
180o rotation along the long axis with approximate dimensions added.
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Domain  II  forms  the  interface  between  hCCS  monomers  and  this  model  adequately 
provides volume to accommodate this interaction. In every model used to generate this 
average there are two regions of mass that are not accounted for by the central domain II. 
These areas must therefore contain domains I and III. The elongated 3D shape reflects the 
observation that the characteristic p(r) function has an asymmetric curve shape with Dmax/2 
being significantly larger than the r-value at peak maximum. Moreover the ab initio shape 
reconstruction  confirms that  the  overall  conformation of  hCCS in  solution displays  no 
obvious overall symmetry.
6.4 Rigid body modelling of hCCS
Given the multi-domains assembly with predicted flexible polypeptide segments of full-
length hCCS it is not expected to exist as a rigid, globular macromolecule in solution. It is 
more likely to exhibit conformational plasticity with domains I and III able to move freely 
with respect to domain II.  In fact this  movement is a necessity if  hCCS is  to perform 
copper transfer by the proposed mechanism. In order to explore the conformational space 
occupied by hCCS and the biologically relevant interactions between these domains their 
arrangement and positions were modelled by fitting high resolution structures (Table 6.1) 
to the experimentally determined SAXS envelope. This was performed using the program 
BUNCH  204.  The hCCS C-terminus has no associated structure in  the public  databases 
therefore an homology model was constructed using that part of the yCCS C-terminus that 
is visible in the structure of the yCCS-ySOD1 complex (PDB ID: 1JK9).
Name Amino acids Source PDB ID
Domain I Atx1-like 12 – 69 NMR 1QUP
Domain II SOD1-like 88 - 232 Crystal 1DO5
Domain III 250 – 258 Homology model
Table 6.1. The three hCCS domains used in rigid body modelling.
Each different rigid body model generated by this process is consistent with the SAXS data 
as indicated by a very good fit to the experimental scattering profile fit to the experimental 
results (Figure 6.12). These models collectively,  therefore, represent a pool of potential 
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domain arrangements hCCS can adopt in solution. By taking these models together one can 
ascertain the likelihood that a domain will be found in a particular position. Figure 6.13 
indicates that domain I forms a cloud around the central SOD1-like domain II and appears 
to be constrained by the length of the interdomain linker. In contrast however, domain III 
forms an extension into the solvent that is free to move. There is no indication of a domain 
swap between the two hCCS monomers and the possibility of a domain I-I or domain III-
III interaction is also unlikely due to their spatial separation.
Domain I is essential for hCCS mediated incorporation of copper into SOD1 192. Reversible 
copper transfer has been observed between Ctr1 and Atx1 175 and is likely to proceed in a 
similar fashion between Ctr1 and hCCS domain I. The initial stage of copper binding by 
domain I could be achieved by many of the models in Figure 6.13 where domain I is free,  
solvent exposed and receptive. These conformations would permit copper transfer to the 
Atx1-like domain from the C-terminus of hCtr1 while hCCS is in the dimer state. Initial 
acquisition  seems to  occur  independently for  each hCCS monomer  due  to  the  lack  of 
interaction between opposing domains.
C-terminal domain III is then able to acquire copper from domain I. This interaction was 
postulated by Eisses et al based on EXAFS data 197 and is necessary if hCCS is to transfer 
copper between the two  192.  Transfer is facilitated by a conformation in which the two 
domains are physically adjacent (Figure 6.14). In this model the copper binding motifs are 
up to 10 Å apart allowing sufficient space for the adoption of a large multi-nuclear copper-
sulphur cluster between the copper binding cysteines of each domain. In the absence of 
SOD1, this cluster formation presents a favourable and secure retention pocket for Cu(I) 
ions  which  may lead  to  a  conformational  change  209 that  facilitates  hCCS homodimer 
dissociation enabling realisation of the SOD1-CCS heterodimer.
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Figure  6.12  Scattering  profile  of  25  rigid  body models  of  full  length  hCCS.  The  hCCS  experimental 
scattering profile with error bars (black) with the computed profile of each individual rigid body model. The 
goodness-of-fit value (χ2) varies between 1.7 and 2.1.
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Figure 6.13. Solution structures of homodimeric hCCS. Twenty-five hCCS structures derived by rigid body 
modelling against experimental SAXS data rotated 180o around the long axis. Domain I is coloured purple, 
II-blue, III-green and copper binding motifs are depicted in red. Taken from Wright et al 193.
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Figure 6.14. Interaction between the copper binding motifs of domains I and III. (A) Detail of the rigid body 
model. (B) Fit to experimental scattering data, χ2 = 1.95. (C) Complete model.
While  the  models  of  hCCS presented  here  lend  themselves  to  a  demonstration  of  the 
feasibility  of  copper  movement  between  domains  I  and  II  they  do  not  represent  the 
complete spectrum of possible conformations. It is possible a mixture of conformations 
exist  that satisfy the experimental  data in totality but individually do not.  Thus hyper-
extended and compact structures may coexist in solution but which are not described in the 
pool of structures in Figure 6.13. Currently there is no substantiated and non-circuitous 
route with which to determine the composition of such a conformationally heterogeneous 
solution for oligomeric proteins.
6.5 Characterisation of human SOD1 by small angle X-ray scattering
Small-angle X-ray scattering has previously been used to characterise wild-type SOD1 and 
several fALS associated SOD1 mutants 89,212. Large differences between wtSOD1 and A4V 
and I113T SOD1 mutants have been reported. These differences are illustrated by highly 
variable deduced scattering parameters and unusual perturbations in the proposed structural 
models of these two SOD1 variants. These parameters may have been affected by variable 
metal content and aggregation of the sample, two factors common to SOD1. To address 
this possibility and in order to make a valid comparison between SOD1, hCCS and their 
complex,  wtSOD1  and  two  variants,  each  with  well  defined  metallation  state,  were 
analysed  by  small-angle  X-ray  scattering  in  conjunction  with  size  exclusion 
chromatography.
Figure 8.1 depicts the scattering profile of wild-type, L38V and I113T SOD1 in the copper-
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apo,  zinc-holo  state.  These  profiles  are  of  high  quality  with  little  experimental  error 
throughout the length of the curves. Comparison of each scattering profile shows little 
difference (Figure 8.2). The previously reported Rg and Dmax values for wtSOD1 are 20.6 Å 
212 and 68 Å 89 respectively which compare well with the values reported here, 20.6 Å and 
60 Å. The reported values for I113T SOD1 are however 22.9 Å and 82 Å 89 and seem to 
indicate a much less compact protein than those deduced here, 20.8 Å and 64 Å.
Hough et al reported a characteristic feature of the SOD1 scattering curve, a minimum at q 
= 0.25 Å-1 89. This feature was found to be smoothed in the case of I113T SOD1 indicating 
a loss of structural integrity. There is no evidence in Figure 8.1B and C of such an effect in 
the I113T and L38V SOD1 mutants in comparison with wild-type.
Several lines of enquiry have implicated incorrect folding or protein unfolding in SOD1 
fALS pathogenesis particularly when metal depleted 90,213,214. Figure 8.3 portrays the Kratky 
analysis for the SOD1 proteins described above. In this case, L38V and I113T have almost 
identical  Kratky plots  when compared  with  wtSOD1 indicating  that  all  three  of  these 
SOD1 proteins are equally well folded.
The  lack  of  any  gross  structural  perturbations  resulting  from  the  L38V  and  I113T 
mutations is confirmed by their  ab initio shape reconstruction models (Figure 8.4). The 
dimeric nature of wtSOD1 is clearly visible in these structures as with the two mutants. 
However  as  the  two SOD1 mutants  are  rotated along their  long axis  their  widths  and 
breadths appear to vary slightly with respect to wild-type SOD1. As the differences among 
the three scattering profiles (Figure 6.16) and structural parameters (Table 8.1) are not 
significant this is likely to result from slight variations in the shape restoration process 
rather than structural changes to the SOD1 molecules.
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Figure 6.15. The scattering profile of human SOD1. (A) wtSOD1, (B) L38V SOD1 and (C) I113T SOD1.
Figure 6.16. Comparison of the scattering profile of wild-type, L38V and I113T copper-apo zinc-holo SOD1.
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Figure 6.17. Kratky analysis of recombinant zinc loaded wild-type, L38V and I113T SOD1. The Kratky plot  
is normalised for the height of the peak maxima.
Figure 6.18. Small-angle X-ray scattering shape restoration models of human SOD1. (A) wtSOD1, (B) L38V 
SOD1 and (C) I113T SOD1. A two-fold symmetry axis was imposed on model building.
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Figure 6.19. Comparison of the experimental scattering profile of I113T SOD1 with the predicted profile  
deduced from its crystal structure (1UXL).
The solution structure of I113T SOD1 has previously been elucidated and was found to 
have  large  extensions  into  the  solvent  originating  from  each  monomer  89.  The  data 
presented here indicate that L38V and I113T SOD1 have a gross structure very similar to 
that of wild-type with no evidence of these structural perturbations. Figure 6.19 compares 
the  experimentally  obtained  scattering  profile  of  I113T SOD1 with  that  of  the  profile 
deduced  from its  crystal  structure  (1UXL).  It  can  clearly  be  seen  from this  plot  that 
experimental and deduced profiles are very similar indicating that the protein does not 
adopt a conformation in solution different from that observed in the crystal.
There are two probable contributors to the discrepancy between the results described here 
and  those  of  Hough  et  al 89.   Recombinant  SOD1  expression  in  E.  coli facilitates 
homogeneous metal loading, with the purified protein being more than 99 % copper-apo, 
zinc-holo. This results from the low copper concentration in standard LB media and the 
lack of a CCS bacterial homolog. Conversely, zinc is available and SOD1 seems able to 
bind it without the necessity of a zinc loading mechanism. The I113T SOD1 characterised 
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previously was expressed in  S. cereviseae where it is metallated in a fashion akin to the 
situation in humans. In effect this means incomplete zinc and partial copper metallation.
Secondly, SOD1 is known to be aggregation prone, especially in its apo state. The inflated 
Rg and  Dmax values previously stated for both A4V and I113T SOD1 89 are most likely a 
result  of  the presence of  larger  molecular  weight  species  than the  SOD1 dimer  in  the 
experimental  sample.  These species need only be trimers or tetramers,  for example,  in 
order to unduly effect the calculated Rg and Dmax toward larger values without giving rise to 
the  obvious  signs  of  protein  aggregation  commonly  observed  in  SAXS  experiments. 
Homogenous  metallation  and  protein  separation  immediately  prior  to  data  collection 
undoubtedly contributes to the concurrence of the scattering profiles presented here.
It must be concluded that there is no observable reorientation of the SOD1 monomers or 
large  conformational  changes  that  take  place  when  SOD1 carries  the  L38V or  I113T 
mutation  when  it  is  metallated  as  described  above.  As  SAXS  visualises  the  average 
structure present  in a solution these results  do not eliminate the possibility that  a sub-
population have perturbed and pathogenic structural features. 
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Chapter VII
Structural characterisation of the hCCS-SOD1 heterodimer by 
solution X-ray scattering
7.1 Construction of the hCCS-SOD1 heterodimer
Heterodimer formation between SOD1 and its chaperone has previously been documented 
for both yeast and human systems 208,215. Both of these experiments used artificial copper 
site mutants to promote stable complex formation. The methodology used by these groups 
was followed here for the formation of the wild-type SOD1 containing complex with the 
addition  of  an  incubation  of  SOD1  with  reductant  before  mixing  with  hCCS.  This 
incubation was necessary to reduce the SOD1 intra-subunit disulphide and 5 mM DTT at 
room temperature for a minimum of 4 hours was sufficient.
Complexation between hCCS and H46R/H48Q human SOD1 proceeds at stoichiometric 
protein ratios however yeast H48F and wild-type SOD1 require a 2 fold excess  208,215. 
Here, heterodimer formation between human I113T, L38V and wtSOD1 was most effective 
with a 1.5 molar excess of SOD1. Figure 7.1A shows analysis of the wild-type complex by 
gel filtration. The size exclusion chromatography UV absorption trace obtained from the 
separation of 100 μM hCCS mixed with 150 μM reduced wtSOD1 indicates a maximum at 
85ml. This peak is positioned between those obtained when either 100 μM hCCS (79 ml) 
or 150 μM wtSOD1 (90 ml) were loaded separately indicating the presence of a species of 
intermediate size. SDS-PAGE analysis of fractions taken over the course of this elution 
(Figure  7.1C)  show clearly the  presence  of  both  hCCS and SOD1 in this  region.  For 
comparison,  SDS-PAGE  of  fractions  taken  from  hCCS  and  SOD1  loaded  singly  is 
presented in Figure 7.1B and C.
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Figure 7.1. Size exclusion chromatographic and SDS-PAGE analysis of the hCCS-wtSOD1 heterodimer. (A) 
SEC profiles of 100 μM hCCS, 150 μM wild-type SOD1 and the hCCS-wtSOD1 complex constructed with 
100 μM hCCS and 150 μM wtSOD1. 1 ml fraction were taken over the course of elution from 72 ml to 98 
ml. (B) SDS-PAGE analysis of fractions from SEC of 100 μM hCCS. (C) SDS-PAGE analysis of fractions 
from SEC of  hCCS-wtSOD1 heterodimer made with 100  μM hCCS and 150 μM SOD1. (D) SDS-PAGE 
analysis of fractions from SEC of 150 μM wtSOD1.
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Figure 7.2. Size exclusion chromatography of the hCCS-SOD1 complex after purification and concentration. 
Three complexation experiments represented by Figure 7.1A-blue were pooled and incubated overnight at 4 
oC before concentrating to a 1 ml volume and reapplication to a Superdex 200 16/60 column.
Figure 7.1A-blue shows two clear shoulders on the hCCS-wtSOD1 complex gel filtration 
trace at positions where the maxima for homodimeric hCCS and SOD1 are found when 
loaded  singly.  These  represent  the  native  homodimer  for  each  species  and  may  be 
attributed to  incomplete  reduction  of  the SOD1 disulphide.  An extended incubation  of 
SOD1 with increased DTT did not promote complete complex formation. This would seem 
to indicate a dynamic equilibrium with approximately 10 % of each species remaining as 
the  homodimer.  Conversely,  isolation  of  fractions  corresponding  to  the  hCCS-SOD1 
complex followed by incubation overnight at 4 oC and concentration before reapplication 
to the size exclusion chromatography column did not re-establish the equlibrium; the vast 
majority of protein remained in the heterodimeric state (Figure 7.2). A small amount of 
homodimeric hCCS is visible as a shoulder at 79 ml on this trace but this is likely to arise 
from  incomplete  separation  at  the  previous  gel  filtration  step  and  underscores  the 
importance of the SEC-SAXS methodology used in the following sections.
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7.2 SAXS data collection and assignment of structural parameters
Small-angle X-ray scattering data for the human CCS-SOD1 complex was collected at the 
SWING beamline at  synchrotron SOLEIL replicating the methodology employed when 
measuring the hCCS homodimer with the exception of the size exclusion chromatography 
column. This change, to a Superdex 200 16/60 gel filtration column, was affected in order 
to maximise separation of the two homodimers from the heterodimer of interest.
Scattering  was  recorded  from hCCS  complexed  with  wild-type  SOD1 and  two  fALS 
associated SOD1 mutants, L38V and I113T (Figure 7.3). Guinier analysis of the hCCS-
wtSOD1 scattering profile indicates a radius of gyration for the complex of 24.8 ± 0.3 Å, 
indicating a dimer of size midway between the SOD1 and the hCCS  homodimers. The 
distance distribution function indicates a maximum particle dimension (Dmax) of 89 ± 3Å 
(Figure 7.4).  A comparison of  structural  parameters  deduced from SAXS for the three 
complexes studied here is presented in Table 7.1.
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Figure 7.3. Scattering profile of hCCS complexed with SOD1. (A) hCCS-wtSOD1, (B) hCCS-L38V SOD1 
and (C) hCCS-I113T SOD1. Experimental scattering with error bars are shown in black with the regularised 
scattering profile in blue.
Figure 7.4. Distance distribution function of hCCS complexed with SOD1. (A) hCCS-wtSOD1, (B) hCCS-
L38V SOD1 and (C) hCCS-I113T SOD1.
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Complex Real space Rg (Å) Dmax (Å)
hCCS-wtSOD1 24.9 ± 0.3 89 ± 3
hCCS-L38V SOD1 24.9 ± 0.3 87 ± 3
hCCS-I113T SOD1 24.6 ± 0.3 82 ± 3
Table 7.1. Comparison of deduced scattering parameters for three hCCS-SOD1 complexes.
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7.3 Ab initio model reconstructions
The scattering profiles of hCCS complexed with wtSOD1, L38V and I113T SOD1 were 
used to create ab initio bead models for each heterodimer. As in the previous chapter, 20 
models were generated for each complex using the GASBOR algorithm  203.  Figure 7.5 
presents reconstructed three-dimensional models for the hCCS-wtSOD1 complex. For each 
complex the restored shape models were superimposed, compared and averaged (Figures 
7.6 and 7.7).
Figure 7.5. Ab initio bead models of the hCCS-wtSOD1 complex. 8.8<χ2<13.4.
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Figure 7.6. The 'most typical' hCCS-wtSOD1 complex model. This hCCS-wtSOD1 ab initio model was used 
as the reference model during averaging of those models presented in the previous figure. The goodness-of-
fit value in comparison to the experimental scattering profile is  χ2=11.4.
Figure 7.7. Averaged ab initio shape restorations of hCCS complexed with SOD1. (A) wtSOD1, (B) L38V 
SOD1 and (C) I113T SOD1.
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Ab initio shape restoration from solution X-ray scattering allows one to create a consensus 
model of the subject protein in solution. Figure 7.7 indicates that this consensus shape is 
subtly different for L38V and I113T SOD1 when compared with wtSOD1 complexed with 
hCCS.  Each  model  is  elongated  in  one  dimension,  as  dictated  by  the  p(r)  function, 
however both mutant complexes have a more globular appearance than the contoured wild-
type form. This discrepancy is not observed when comparing the three-dimensional shapes 
reconstituted from the scattering profiles of wild-type, L38V and I113T homodimers as 
described in the previous chapter. H80R and D124V SOD1 mutants have previously been 
observed to have perturbed interactions with the SOD1 copper chaperone characterised by 
abrogation  of  copper  loading  216. While  L38V and I113T are  known to  be  adequately 
copper loaded  in vivo,  assessing the state of the SOD1 intrasubunit  disulphide bond is 
difficult. hCCS catalyses oxidation of cysteines 57 and 146 to form the SOD1 disulphide 
and  improper  oxidation  is  thought  to  be  a  contributor  to  mutant  SOD1 pathogenicity. 
Perhaps  the  contrast  between  these  structures  is  a  manifestation  of  altered  interaction 
characteristics  between  hCCS  domain  II  and  mutant  SOD1.  If  this  were  the  case, 
responsibility for SOD1 instability would not be a propensity for disulphide reduction of 
the fully post-translationally modified protein but a disturbance in the SOD1 maturation 
pathway.
7.4 Rigid body modelling the hCCS-wtSOD1 complex
Complex formation between SOD1 and CCS is  known to be reliant on the SOD1-like 
domain of hCCS with domain III completing transfer of copper to the SOD1 active site. 
Using a rigid body modelling approach to curve fitting against the experimental scattering 
data presented thus far in conjunction with the domain structures of hCCS described in 
Chapter 6, Table 6.1 and crystal structures of I113T, L38V and wtSOD1 the conformational 
flexibility of the hCCS-SOD1 complex was sampled (Figure 7.8).
This composite of conformations is similar to that of homodimeric hCCS presented in the 
previous chapter. The Atx1-like domain I is mobile but forms a region of high probability 
of presence adjacent to, and curved around, one half  of the dimer interface.  Of the 20 
models  presented,  there  is  one  exception  to  this  where  domain  I  is  moved across  the 
interface. Domain III appears to have a greater degree of freedom and can be found at any 
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point surrounding the two domains that comprise the interface. The computed scattering 
profile for each hCCS-wtSOD1 rigid body model is represented in Figure 7.9 and show an 
excellent agreement with the experimental profile. 
Comparison of these models with the crystal structure of the yCCS-ySOD1 H48F complex 
(PDB ID: 1JK9 199) indicates they occupy very similar conformational space (Figure 7.10). 
The SOD1-CCS interface is tethered in the rigid body models and accordingly shows high 
structural homology between the human and yeast complexes. Most interestingly, domain I 
of the yeast complex is found within a space densely populated with multiple possible 
positions  of  domain  I  from the human solution  structures.  This  congruence effectively 
validates the modelling process used here as the initial position of domain I at the start of 
the modelling procedure was distant from this region of high probability of presence.
In the crystal structure of the yeast complex, domain III stretches across the unit cell to 
make a number of contacts with the SOD1-like domain of a second heterodimer. Domain 
III is found to be very mobile in the solution structures presented here however one model 
shows this domain in a position close to that observed in the yeast structure. This further 
indicates  an  effective  modelling  protocol  and  the  complementarity  of  differing 
experimental protocols.
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Figure  7.8.  Solution  structures  of  the  hCCS-wtSOD1  complex.  Models  were  generated  against 
experimentally  obtained  SAXS  data.  20  models  are  aligned  according  to  the  central  domain  II-SOD1 
interface and overlaid showing the varying domain arrangement of hCCS when complexed with wild-type  
SOD1. Colour  coding follows Figure 6.13 where  hCCS domain  I  is  coloured purple,  II-blue,  III-green,  
copper binding motifs are depicted in red and SOD1 is gold.
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Figure 7.9. Scattering profile for the 20 rigid body models of hCCS-wtSOD1, shown in Figure 7.8. The 
experimental scattering profile of the complex is given with error bars (black) with the computed profile of 
each individual rigid body model (multi-coloured). Their goodness of-fit-values range from 2.2<χ2<2.6.
Figure 7.10. Comparison of SAXS solution structures of the human CCS-wtSOD1 complex with the crystal  
structure of the  S. cerevisiae complex. The yCCS-ySOD1 H48F structure (PDB ID: 1JK9), represented in 
pink, is aligned with the 20 rigid body models of the human complex described in Figures 7.8 and 7.9. 
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Figure 7.11. Association of hCCS domain III with SOD1. Detail of four rigid body models showing  the  
hCCS domain III in green, the SOD1 monomer in gold. (A), (B), and (C) The copper binding motif of hCCS 
domain III is able to approach the SOD1 disulphide and active sites, (D) Domain III is wrapped around the 
SOD1 monomer.
While atomic domain models were used in the generation of these structures their atomic 
resolution is lost when they are used to ascertain global domain movements through rigid 
body modelling. Consequently the precise molecular mechanism by which hCCS domain 
III transfers copper to the SOD1 active site cannot be inferred from these structures. These 
structures do however represent a pool of possible domain arrangements hCCS-wtSOD1 
could adopt in solution. Within this cohort several structures can be found where the hCCS 
domain III is proximal to the SOD1 copper active site and the intra-subunit disulphide. 
These  structures  are  represented  individually in  Figure 7.11.  The distance between the 
SOD1  copper  centre  and  the  CXC  motif  of  hCCS  domain  III  is,  at  its  shortest, 
approximately 10  Å (Figure  7.11A).  At  first  glance  this  distance  appears  too  long for 
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effective transfer of copper.  Two factors will  enable this  distance to be bridged during 
copper transfer. Firstly, as described in the previous chapter, the copper-sulphur clusters 
utilised by hCCS are much larger  than mononuclear  copper.  Secondly,  prior  to  copper 
loading  and  disulphide  transfer  from  hCCS,  SOD1  is  immature.  In  this  state  the 
electrostatic loop and disulphide sub-loop are mobile and will not offer the steric resistance 
they exert in the rigid SOD1 structure used here. Consequently, hCCS domain III will be 
able to move into the region these loops occupy in the static crystal structure where it  
would be very close to the SOD1 active site.
7.5 Rigid body modelling the I113T and L38V SOD1-hCCS complex
Immature SOD1 is conjectured to be a crucial factor in the pathogenesis of amyotrophic 
lateral  sclerosis.  fALS associated SOD1 mutants have been observed to have activities 
ranging from nil to more than the wild-type enzyme and copper metallation which varies 
from nil  to  similar  to  wild-type  indicating  SOD1 mediated  fALS has  little  to  do with 
superoxide dismutase activity. SOD1 disulphide reduction is, however, known to heavily 
effect  the stability of  the  protein  in  vitro.  hCCS is  responsible  for  the  transfer  of  this 
stabilising intra-subunit disulphide therefore incomplete SOD1 maturation in vivo resulting 
from an atypical SOD1-CCS interaction could be an initiating factor of ALS.
In order to assess the interaction between hCCS and SOD1 mutants the complex was made 
and measured by SEC-SAXS using L38V and I113T as described in the previous sections. 
As with the wild-type complex a rigid body modelling approach was then used to probe the 
structure of these complexes. The scattering profiles of L38V and I113T SOD1 complexed 
with hCCS are presented in Figures 7.12 and 7.13.
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Figure 7.12. Scattering profile of 20 hCCS-L38V SOD1 models. Deduced scattering profiles (multicoloured) 
are superimposed on the experimental scattering profile of the complex with errors bars (black). Goodness-
of-fit values are 3.4<χ2<4.1.
Figure 7.13. Scattering profile of 20 hCCS-I113T SOD1 models. Deduced scattering profiles (multicoloured) 
are superimposed on the experimental  scattering profile of the complex overlaid with error bars (black).  
Goodness-of-fit values are 5.9<χ2<9.4
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Figures 7.14 and 7.15 show an overlay of 20 rigid body models of hCCS complexed with 
L38V and I113T SOD1 respectively. hCCS-L38V SOD1 adopts similar conformations in 
comparison with the wild-type complex.  Domain I  is  found encircling one half  of  the 
complex interface while domain III is more mobile and can be found almost anywhere 
surrounding the interface domains. The overlapping positions of these domains when all 20 
models are superimposed emphasises the possibility of an interaction between their copper 
binding motifs.
The I113T SOD1 complex is markedly different however (Figure 7.15). In this instance, 
domain III no longer forms extended protrusions into the solvent seemingly hindered only 
by  the  length  of  its  polypeptide  chain  but  congregates  close  to  the  SOD1  monomer. 
Consequently the complex appears smaller and more compact. Furthermore, there is little 
interaction between domains I and III with both forming separate, distinct regions where 
there is a high probability of their presence.
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Figure 7.14. Solution structures of the hCCS-L38V SOD1 complex. 20 models are overlaid showing the 
domain arrangement of hCCS when complexed with SOD1. Gold – SOD1, purple – hCCS Atx1-like domain 
I, blue – hCCS SOD1-like domain II, green – hCCS domain III, red – hCCS copper binding motif.
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Figure 7.15. Solution structures of the hCCS-I113T SOD1 complex. 20 models are overlaid showing the 
domain arrangement of hCCS when complexed with SOD1. Gold – SOD1, purple – hCCS Atx1-like domain 
I, blue – hCCS SOD1-like domain II, green – hCCS domain III, red – hCCS copper binding motif.
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7.6 Comparison of the solution structures of SOD1, hCCS and the hCCS-SOD1 
complex
The data presented in the preceding chapters present an unparalleled opportunity for the 
first  time to compare the solution structures  of  human CCS, SOD1 and the functional 
complex critical in the maturation of SOD1. Given the wealth of information implicating 
immature mutant SOD1 in the pathogenesis of amyotrophic lateral sclerosis this is also a 
unique opportunity to probe the structure of mutant SOD1-CCS for the crucial differences 
which may effect SOD1 maturation.
Figure 7.16A describes the scattering profile of SOD1, hCCS and the heterodimeric hCCS-
SOD1 complex. The wtSOD1 profile shows the minimum at q = 0.25 Å-1 characteristic of 
the  ellipsoidal  SOD1 shape.  While  both  homodimeric  hCCS and the  complex  show a 
comparable trait, this characteristic of the scattering curve it is less pronounced in both 
instances but its presence can be attributed to both SOD1 and the SOD1-like domain in the 
complex and homodimer respectively. There is an increase in the number of characteristic 
features present in the scattering curves of hCCS and hCCS-SOD1 compared with SOD1 
and  this  parallels  an  increase  in  the  molecular  and  conformational  complexity  of  the 
proteins.
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Figure 7.16. Scattering profiles of hCCS, SOD1 and their heterodimeric complex. (A) Scattering profile, (B) 
Distance distribution function and (C) Kratky plot. The scattering profile, P(r) function and Kratky plot are 
normalised to unity at the peak maxima.
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Complex Real space Rg (Å) Dmax (Å)
wtSOD1 20.6 ± 0.2 60 ± 2
L38V SOD1 20.7 ± 0.2 65 ± 2
I113T SOD1 20.8 ± 0.2 64 ± 2
hCCS-wtSOD1 24.9 ± 0.3 89 ± 3
hCCS-L38V SOD1 24.9 ± 0.3 87 ± 3
hCCS-I113T SOD1 24.6 ± 0.3 82 ± 3
hCCS 31.3 ± 0.3 118 ± 4
Table 7.2 Deduced scattering parameters for SOD1, hCCS and their heterodimeric complex. 
The p(r) function of wtSOD1 in Figure 7.16B is indicative of a protein comprised of two 
domains in close contact with each other and a slight elongation. Similarly the distance 
distribution  function  of  the  hCCS-SOD1  complex  can  be  equated  with  a  protein  of 
effectively  3  domains  further  indicating  that  the  third  hCCS domain  does  not  form a 
compact globular structure. Due to the number of domains present in the hCCS homodimer 
it  is  difficult  to  distinguish features in the  p(r)  function however the protein is  clearly 
elongated.  In  general  and  unsurprisingly,  as  CCS  monomers  are  added  and  SOD1 
monomers are removed the oligomer becomes more elongated and more complex. This 
notion is reflected in Table 7.2 which also describes the effect of adding mutant SOD1 
rather than the wild-type protein.
Table  7.2  highlights  a  counterintuitive  aspect  of  hCCS-SOD1  heterodimer  formation. 
Mutant homodimeric SOD1 proteins had slightly larger Dmax values the wild-type enzyme. 
On the other hand, the heterodimeric complexes they form with hCCS have smaller  Dmax 
when compared with the wild-type complex. Indeed the wild-type complex is 8 % longer 
than the complex formed with I113T SOD1.
To  draw further  contrast  between  wild-type  and  I113T SOD1 complexed  with  hCCS, 
Figure 7.17 describe the likely positions of the hCCS Atx1-like domain when complexed 
with these two SOD1 variants.
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Figure 7.17. Comparison of the positions of the hCCS Atx1-like domain I when complexed with wtSOD1 
and I113T SOD1. Grey - the central dimer interface comprised by a hCCS SOD1-like domain II and a SOD1 
monomer. Blue – the hCCS domain I when complexed with wtSOD1. Red – the hCCS domain I when 
complexed with I113T SOD1. In each case 20 models are presented aligned according to the central SOD1-
domainII interace each resulting from rigid body refinement against experimental scattering data.
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Figure 7.18. Comparison of the positions of the hCCS Atx1-like domain I when complexed with wtSOD1 
and L38V SOD1. Grey - the central dimer interface comprised by a hCCS SOD1-like domain II and a SOD1  
monomer. Blue – the hCCS domain I when complexed with wtSOD1. Red – the hCCS domain I when 
complexed  with  L38V  SOD1.  In  each  case  20  models  are  presented  each  resulting  from  rigid  body 
refinement against experimental scattering.
Figure 7.19. Comparison of the positions of the hCCS domain III when complexed with both wtSOD1 (blue) 
and I113T SOD1 (red). The central dimer interface comprised by a hCCS SOD1-like domain II and a SOD1 
monomer is in grey.
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For both hCCS-wtSOD1 and hCCS-I113T SOD1 complexes  one can  identify a  region 
where the Atx1-like domain is found with high probability. As can be clearly seen in Figure 
7.17 these regions are found to adjoin, with some overlap, but are predominantly distinct. 
What overlap exists is fostered by the seemingly more mobile domain I of the wild-type 
complex. The hCCS-L38V complex does not undergo such a dramatic shift in the position 
of the Atx-1like hCCS domain I, therefore the distinction between wild-type and L38V 
complex is less severe with a greater degree of overlap (Figure 7.18).
The copper binding motif at the C-terminus of hCCS is essential for SOD1 copper loading 
191. Figure 7.19 compares the positions of this domain when hCCS is complexed with wild-
type and I113T SOD1. As described in the preceding sections the C-terminal domain of the 
wild-type complex is restricted only by its length and can be found surrounding the dimer 
domains. In complete contrast the hCCS C-terminus when complexed with I113T SOD1 
appears restricted to a region of high probability of presence close to the SOD1 monomer
Figure 7.20. Comparison of the X-ray scattering profiles of wild-type, L38V and I113T SOD1 complexed 
with hCCS.
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Given  that  the  SOD1  mutations  used  herein  are  single  point  mutations,  is  there  any 
justification  from the  scattering  profile  of  the  complex  for  such  a  significant  domain 
rearrangement?  Figure  7.3  shows  the  X-ray  scattering  profile  for  each  hCCS-SOD1 
complex  discussed.  A comparison  of  their  smoothed  scattering  profiles  (Figure  7.20) 
indicates that the complexes are indistinguishable by eye at low angles, q < 0.2 Å-1. In this 
region  scattering  intensity  is  determined  by  the  scatterer's  shape  and  size.  At  higher 
scattering angles, q > 0.2 Å-1, due to the use of a logarithmic scale differences in the three 
profiles become obvious. In this region scattering intensity is dictated by intramolecular 
characteristics  and  the  differences  between  the  three  profiles  infer  a  change  in  those 
characteristics.
While the low angle scattering is determined by the scatterers shape and size the higher 
angle is determined by conformations and interactions so it is reasonable infer that there 
should be differences between the complexes based on their scattering patterns.
These observations and comparisons lead to either of two conclusions. Movement of the 
Atx1-like domain into a region close to the hCCS domain II in the I113T SOD1-hCCS 
complex restrains the motility of domain III, or, retention of domain III in a region close to 
the SOD1 monomer pushes the Atx1-like domain out of the area it would normally occupy 
in the wild-type complex.
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Chapter VIII
Discussion of X-ray solution scattering based structure 
determination of SOD1, hCCS and their complex
8.1 A comparison of hCCS scattering profiles collected at different X-ray sources and 
SAXS stations
The work described here is the first structural characterisation of full-length human CCS in 
solution. hCCS has implications for both the pathogenesis of amyotrophic lateral sclerosis 
and  copper  metabolism.  This  protein  has  been  known  for  over  a  decade  and  has 
consistently rebutted structural characterisation by several respected groups. What follows 
is a review of the implications of the results in the previous chapters.
Small  angle  X-ray  scattering  is  the  choice  method  for  studying  large,  biological 
macromolecules in solution. In 2004,  Mathew et al  217 documented a combination of the 
standard SAXS technology with size exclusion chromatography apparatus. This synthesis 
facilitates  the  separation  of  impurities,  different  oligomeric  states  and   aberrant  high 
molecular weight aggregates from the species of interest, by gel filtration, directly before 
exposure to the x-ray beam  217. It also eliminates any averaging contribution from such 
species  and  prevents  buffer  mismatch  between  blank  and  sample  through  the  buffer 
exchange  effect  of  size  exclusion  chromatography.  To  date  three  X-ray  scattering 
beamlines have this capability: BioCAT at APS Chicago (US) 217, BL-10 at Photon Factory 
Tsukuba (Japan) 218 and SWING at SOLEIL St Aubin (France) 211.
Traditional, static SAXS analysis of recombinant hCCS at synchrotron SAXS stations 4-2 
at SSRL (US)  219 and BL45XU at SPring-8 RIKEN (Japan)  220 yielded incongruence in 
scattering profile (Figure 8.1) and deduced structural parameters (Table 8.1 & Figure 8.2), 
such as a substantially increased value for the radius of gyration (Rg), indicating a problem 
with sample monodispersity. The decision to use the SEC-SAXS approach, and therefore 
the SWING beamline, was a direct result of these initial experiments.
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Figure  8.1.  Comparison  of  smoothed  scattering  profiles  from  hCCS  collected  at  three  different  SAXS 
beamlines. Curves are normalised to I(q)=1 at q=0.
Figure 8.2 Comparison of Guinier plots for hCCS measured at three beamlines. Adapted from Wright et al 193.
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Synchrotron SPring-8 SSRL SOLEIL
Beamline BL45XU 220 BL4-2 219 SWING 211
Real space Rg (Å) 58.7 38.3 31.4
Dmax (Å) 174 160 118
Table 8.1. Deduced SAXS parameters for hCCS measured at three beamlines.
Figure 6.3 and 6.4 indicate the reason for these disparities. In solution the hCCS dimer 
predominates  but  is  joined  by a  small  amount  of  tetrameric  protein  and  often  higher 
molecule  weight  aggregates.  These  higher  molecular  weight  species  disproportionately 
affect  scattering  making  the  protein  appear  larger  or  less  compact  than  it  actually  is. 
Without the combined SEC-SAXS approach recording scattering from dimeric hCCS alone 
would be very inaccurate.
Similarly,  collecting  scattering  data  from  the  hCCS-SOD1  complex  would  also  be 
impossible  due  to  incomplete  formation  of  the  heterodimer.  As  scattering  from  bulk 
solutions  is  an average,  measurements  taken from the hCCS-SOD1 heterodimer would 
comprise scattering from at least three species and any deductions made as a result would 
be disputable.
8.2 The function of hCCS and its intrinsic flexibility
The domain  structure  of  hCCS is  crucial  for  the  transport  and loading of  copper  into 
SOD1.  In  both  the  homodimeric  and  heterodimeric  states  hCCS  exhibits  extensive 
conformational flexibility made possible by two disordered, glycine rich linker regions of 
11 and 17 amino acids. Indeed, hCCS domain III is largely disordered in structures of yeast 
CCS and homology structure predictions of hCCS other than a short α-helix that forms a 
long 42 amino acid flexible tail.
CCS conformational flexibility is highlighted by a comparison of the position of the Atx1-
like domain I  in  the crystal  structures  of  the yCCS homodimer and the yCCS-ySOD1 
heterodimer (Figure 8.3). The linker between domain I and II in the yeast homolog is 6 
amino  acids  long  in  comparison  with  11  found  in  hCCS.  As  a  crystal  structure  is  a 
repeating assembly of molecules in a low energy state it can be expected that human CCS 
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will therefore be considerably more plastic in solution.
This flexibility is key if hCCS is to function as the accepted model of copper transfer to 
SOD1 suggests. The sequence of this transfer has been devised and hinges on a few key 
experimental observations.
Figure 8.3 Comparison of one yCCS monomer from the crystal structures of the yCCS dimer (cyan) and the  
yCCS-ySOD1 complex  (pink).  The models  (1JK9 and 1QUP respectively)  are  aligned  according to  the 
SOD1-like domain II.
Firstly,  the  CXC motif  of  domain  III  is  essential  for  SOD1 copper  loading  under  all 
conditions  191.  This  crucial  region  is  therefore  responsible  for  the  ultimate  transfer  of 
copper to the SOD1 active site.
Secondly, domain I has 37 % identity to the yeast Atx-1 protein. The yeast Atx1 protein is 
known  to  exchange  copper  with  the  cytoplasmic  domain  of  the  membrane  copper 
transporter, Ctr1  175. By analogy one would expect hCCS to perform the same function; 
initial copper acquisition.
Deletion of the Atx1-like domain I ablates hCCS function  in vivo.  This point has been 
disputed  on  the  following  basis.  Schmidt  et  al reported  this  region  of  the  yeast  CCS 
homolog is only necessary under copper limited conditions 191. In fact the copper limited 
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conditions  used in  yeast  culture by these  experimenters  was 10  μM. While  this  is  the 
extracellular concentration, it is safe to assume the intracellular free copper concentration 
will  vastly  exceed  the  10-18 M  concentration  known  to  exist  under  regular  culture 
conditions  168.  This  copper  flood  understandably  bypasses  the  need  for  domain  I. 
Conversely,  in  vivo experiments on the human protein in  human fibroblasts  found this 
domain to be indispensable for SOD1 activation 192.
Perhaps because of this misapprehension, domain I has been proposed to function as an 
interaction mediator that would enable stable complex formation, with Ctr1 for example, 
and thus enable direct copper loading to domain III  221.  This notion is dismissed by the 
observation that domain I is able to perform its function in trans when co-expressed with a 
yCCS domain II/III truncation 191.
Thirdly, the interaction between hCCS and SOD1 is mediated by the amino acids at the 
CCS  domain  II  and  SOD1 homodimer  interfaces  and  the  SOD1 in  question  is  fully 
translated  when  loading  occurs  222. Consequently,  hCCS-SOD1  complex  formation 
necessitates monomerisation of the native dimers.
Fourthly,  the functional complex between hCCS and SOD1 is a heterodimer.  Although 
crystallisation of the yeast complex yielded a tetramer in the unit cell this was thought to 
be an artefact of crystal packing 215. As described in Chapter 8, and prior to this study 208, 
when  analysed  by size  exclusion  chromatography the  hCCS-SOD1 complex  runs  at  a 
position  between  the  hCCS  and  SOD1  homodimer  indicating  a  protein  complex  of 
intermediate size.
The commonly accepted  81,199,209 process of SOD1 activation and disulphide reduction by 
CCS can be summarised as follows:
1. Domain I recognises the Ctr1 cytoplasmic tail and is loaded with copper (Cu I).
2. The cysteines of domain I and III form a copper conjugate.
3. SOD1 and hCCS undergo monomerisation and heterodimer formation.
4. Copper  is  loaded  into  the  SOD1  active  site  by  domain  III  with  concomitant 
formation of the SOD1 disulphide.
5. The heterodimer disintegrates followed by reformation of the homodimeric species.
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This cycle of SOD1 activation and hCCS recycling is represented in Figure 5.3. Using the 
SAXS derived models presented in the previous chapters it is now possible to observe how 
the  conformational  flexibility  of  hCCS  facilitates  the  multiple  stages  that  take  place 
between copper import by Ctr1 through to SOD1 activation (Figure 8.4).
Initial transfer of copper to hCCS domain I is enabled by a conformation in which the 
whole domain is free and receptive for interactions (Figure 8.4A). The cysteines of the 
copper binding motif of the yeast Atx1 protein  188 adopt a solvent exposed conformation 
which  changes  upon  copper  binding  to  bring  the  copper  ion  into  the  molecule.  This 
conformational change is mimicked by the HAH1 human copper chaperone to a lesser 
extent 187. However the available apo structure of hCCS domain I indicates a one-in-one-
out structure with reference to the copper binding cyteines.
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Figure 8.4. The stages of copper activation of SOD1 by hCCS. (A) The Atx1-like domain I, particularly the  
cycteine rich copper-binding domain, is solvent exposed and available to interact with the copper transporter 
Ctr1. (B) Formation of a domain I-III copper conjugate . (C) hCCS domain III is able to move toward the 
SOD1 active site enabling copper transfer and disulphide transfer in the heterodimeric complex. Purple – 
hCCS domain I, blue – hCCS domain II, green – hCCS domain III, gold – SOD1 and red – copper binding 
motif.
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Both  Atx1  and  HAH1  bind  copper  in  their  monomeric  form  and  directly  load  their 
respective targets without the need for intra-molecular transfer between domains. Transfer 
by  hCCS  is  complicated  by  this  need  to  move  copper  to  domain  III  prior  to  SOD1 
activation so the differences seen at this motif may be accounted for by the need to keep 
copper in a position accessible to domain III.
Figure 8.4B shows an hCCS conformation that would enable copper conjugation by the 
cysteines of domain I and III. This step is not only a necessity to primer domain III ready 
for loading into SOD1 but may also provide a safe environment in which poly-nuclear 
copper clusters can be physically transported from the cell membrane to the places where 
SOD1 is waiting for activation 197.
Figure 8.4C shows that hCCS domain III is able to approach the SOD1 active site. The 
crystal structure of the yeast SOD1-CCS heterodimer indicated that a domain III cysteine 
formed a disulphide with cysteine 57 of a SOD1 monomer a symmetry related heterodimer. 
Here we can see for the first time hCCS domain III interacting with a SOD1 monomer in 
the same heterodimer complex. Domain III is in a position that would facilitate copper 
loading  into  the  SOD1  active  site  but  this  model  does  not  take  account  of  two 
conformational changes:  Firstly,  binding of copper to hCCS domain III  brings about  a 
conformational change which increases its resistance to trypsin digest  209.  Secondly,  the 
electrostatic and zinc binding loops of SOD1 are known to be more dynamic and less rigid 
in the disulphide reduced state. The effect of the former is not known but the latter will  
indubitably open access to the SOD1 active site enabling copper loading and has been 
shown to increase the longevity of the heterocomplex 208.
8.3 Stoichiometry of hCCS-SOD1 complex formation
Previous studies have found that heterodimer formation between CCS and SOD1 occurs in  
vitro at 1:1 and 1:2 molar ratio 208,215. In both of these cases non-natural copper site SOD1 
mutants were used and wild-type SOD1 was not found to form a stable complex. The work 
in the previous chapter elucidates the creation of a stable complex between human CCS 
and wild-type, I113T and L38V SOD1.
Figures 7.1 and 7.2 characterise the production of this complex which is most effective 
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when the hCCS to SOD1 molar ratio was 1:1.5 when first mixed. Initial complex formation 
does not go to completion and homodimeric hCCS and SOD1 can be observed as minority 
species in gel filtration experiments. An obvious cause of this inefficiency would be the 
incomplete reduction of the SOD1 disulphide however longer incubation with a higher 
concentration  of  reductant  did  not  increase  conversion  efficiency.  Conversely, 
homodimeric species did not reform from isolated heterodimer upon long incubation. One 
must conclude that there is a barrier preventing complete complexation but once formed 
the complex is stable.
8.4 The hCCS-SOD1 heterogeneity and implications for ALS
The path  from initial  protein  synthesis  to  a  mature  SOD1 dimer  is  littered  with  post-
translation  modification  events.  While  mature  SOD1  is  the  epitome  of  stability  its 
precursors are  recognised as unstable and aggregation prone with the majority of ALS 
SOD1  mutations  enhancing  this  quality  78,223-225.  The  copper  chaperone  for  SOD1  is 
responsible for two SOD1 modifications: copper loading and disulphide oxidation. The 
presence or absence of the SOD1 catalytic copper centre is not thought to contribute to 
SOD1 disease pathogenesis 226 however the intrasubunit disulphide is of crucial importance 
213,227,228. Reduction of the SOD1 disulphide removes the anchor holding the zinc loop and 
must therefore promote disorder. This may lead to a decreased affinity for the structurally 
important zinc ion  213 or exposure of hydrophobic residues in the core of the molecule 
making it prone to aggregation.
Rather than functionalising freshly translated SOD1 at the ribosome, CCS is thought to 
cycle back and forth between the cell membrane, or an intracellular copper source, and a 
pool  of  pre-existing  immature  protein  222.  hCCS is  not  the only mechanism for  SOD1 
copper activation but 50 % of SOD1 molecules are found to have a reduced disulphide 
when  CCS is  deleted  229.  Thus  disruption  of  this  routine  leads  to  an  accumulation  of 
potentially toxic immature SOD1.
The results presented in the previous chapter indicate structural differences when I113T 
and, to a much less extent L38V, SOD1 is complexed with hCCS in comparison with wild-
type SOD1 however the reasons for this are abstruse. The hCCS-I113T SOD1 heterodimer 
exhibits  a  rearrangement  of  domains  and a  much more  compact  structure.  The linkers 
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which join hCCS domain I  and III  to the central  SOD1-like domain originate  directly 
opposite SOD1 residue 113 in the dimer interface region. The I113T mutation is also found 
at the SOD1 dimer interface which it alters and induces a change in the orientation of the 
two  monomers  89.  This  reorientation  of  monomers  is  also  likely  to  occur  in  the 
heterocomplex due to the similarity of the interface region. Thus it seems that perturbation 
of the hCCS-SOD1 dimer interface precipitates a conformational change in the two copper 
binding hCCS domains perhaps by steric hindrance at the origin of their flexible linkers.
hCCS-I113T SOD1 gives the impression of a complex that is much more globular and 
conformationally less flexible than the wild-type. A close inspection of Figure 7.15 and 
7.19 indicate that hCCS domain III is exclusively found close to the SOD1 monomer in a 
position that would facilitate copper transfer and disulphide oxidation.  These structures 
could be interpreted as domain III being locked in the conformation adopted to transfer 
copper and disulphide. A result of this relatively static conformation is an increase in the 
number of contacts between domain III and SOD1 that would stabilise the heterodimeric 
complex.
In both the yeast and human systems, SOD1 mutants have previously been observed to 
promote stable complexation with hCCS. In both cases these mutations were to the copper 
active sites 208,215. The notion that stable hCCS-SOD1 complexes may prevent proper SOD1 
maturation by sequestering active hCCS has been proposed previously and hinges on the 
excess of SOD1 compared to hCCS  230. This normal imbalance would be exacerbated if 
hCCS was prevented from cycling and would effectively strand the majority of SOD1 in 
the immature, disulphide reduced form. What we see here is the extension of this paradigm 
to include the I113T mutation and by inference, all the dimer interface mutants.
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8.5 Prospects and further work
The work presented here is the first direct evidence of a perturbed interaction between 
hCCS and mutant SOD1. The X-ray scattering studies undertaken here are an important 
foot-hold in this relatively under explored area however there are two important questions 
still to be answered: does this shift in the arrangement of hCCS domains occur with all  
SOD1 mutants  and,  does  the  shift  observed  have  a  pathogenic  effect?  While  the  first 
simply necessitates repetition with a wider cross-section of SOD1 mutants the second is 
more  difficult  to  test.  hCCS-SOD1  complexes  are  notoriously  difficult  to  crystallise 
however the stability of the complexes presented here may facilitate characterisation by 
NMR  methods.  Alternatively,  labelling  either  the  SOD1  or  hCCS  component  before 
complexation may enable dissociation rates to be calculated and compared between the 
wild-type complex and SOD1 mutants.
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Chapter IX
Materials and Methods
9.1 SOD1 cloning and plasmid construction
SOD1 coding DNA was  amplified  by polymerase  chain  reaction  (PCR) using primers 
'SOD1Fwd' and 'SOD1Rev' (Appendix I) with KOD Hotstart DNA polymerase (Novagen) 
from yEP351-hSOD1 plasmid with cycling conditions:
Stage Temperature (oC) Time (s)
Initial Denaturation 95 120
30 cycles
Denaturation 95 15
Annealing 55 15
Elongation 70 15
Terminal Elongation 70 600
Table 9.1 PCR cycling conditions for SOD1 DNA amplification.
PCR products were ligated into pCR-Zeroblunt (Appendix II) plasmid using the Zero Blunt 
PCR Cloning Kit (Invitrogen). Ligation products were transformed into Omnimax2 strain 
E. coli (Appendix III), plated onto selective solid media and incubated at 37 oC overnight. 
Transformants were cultured in selective liquid LB media overnight at 37 oC. Plasmid was 
extracted by Wizard SV Minipreps DNA Purification System (Promega) and sequenced by 
DNA  terminator  reaction  at  GATC  Biotech.  The  resulting  plasmid,  pCR-hSOD1wt 
(Appendix II), was digested at 37 oC for one hour with XbaI and XhoI (NEB) restriction 
enzymes. The 474 bp fragment corresponding to the hSOD1wt DNA was extracted from a 
1% TAE agarose gel after electrophoresis at 120 V for 25 minutes in TAE buffer using 
Wizard SV Gel and PCR Clean-Up System (Promega). Purified SOD1 coding DNA was 
ligated into XbaI-XhoI digested pET303 vector (Appendix II) using T4 DNA ligase (NEB), 
transformed into Omnimax2 strain E. coli, plated onto selective solid media and incubated 
at 37  oC overnight. Transformants were grown overnight at 37  oC in selective liquid LB 
media and plasmids extracted by Wizard SV Minipreps DNA Purification System. Putative 
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pET303-hSOD1wt (Appendix II) plasmids were sequenced by GATC Biotech.
9.2 Site directed mutagenesis
Site directed mutagenesis (SDM) was carried out on pET303-hSOD1wt to introduce the 
I113T  and  L38V  mutations  using Stratagene's  QuikChange  Lightning  Site-Directed 
Mutagenesis Kit (Agilent)  and relevant DNA oligonucleotides (Appendix I). This yielded 
the expression plasmids pET303-hSOD1 I113T and pET303-hSOD1 L38V (Appendix II).
9.3 Expression of recombinant SOD1 proteins
pET303-hSOD1 expression plasmids were transformed in to BL21 (DE3) (Appendix III) 
strain  E. coli.  Transformants were then cultured in selective liquid LB media at  37  oC 
overnight.  10 ml of overnight culture was then transferred into 1 l selective LB liquid 
media and incubated at 37 oC with 220 rpm shaking. When optical density (OD600) ~ 0.5, 
Isopropyl  β-D-1-thiogalactopyranoside  (IPTG)  (Calbiochem)  was  added  to  a  final 
concentration of 0.4 mM. Cultures were then incubated at 25oC with shaking at 220rpm 
overnight.  Cultures were centrifuged at 3000 g for 20 minutes at 4  oC and the cell pellet 
separated from the culture media before freezing at -70 oC for at least 30 minutes or flash 
freezing with liquid nitrogen.
9.4 SOD1 purification
Two strategies were employed to purify recombinant human SOD1 from E. coli. In the first 
instance, cells were resuspended in phenyl-sepharose lysis buffer (KH2PO4 100mM, NaCl 
150mM, lysozyme 0.2mg/ml, DNaseI 10μg/ml, 1 in 1000 protease inhibitor cocktail set III 
(Calbiochem), pH 7.4), lysed by sonication and the soluble and insoluble cell fractions 
were separated by centrifugation at 30,000 g for 2 hours. Chilled ammonium sulphate 4 M 
solution was slowly added to the soluble cell fraction on ice and stirred for 30 minutes 
before  centrifugation  at  8000g for  20  minutes.  The  supernatant  was  then  applied  to  a 
phenyl-sepharose hydrophobic interaction chromatography column pre-equilibrated with 
lysis  buffer  containing  2  M  ammonium  sulphate.  Recombinant  SOD1  was  eluted  by 
gradually decreasing the ammonium sulphate concentration. Fractions were observed by 
SDS-PAGE.  SOD1  containing  fractions  were  pooled  and  dialysed  against  Tris-HCl 
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100mM and 150mM NaCl pH 7.4 before storage at -20oC.
Purification  of  SOD1 for  use in  complexation  experiments  with  hCCS occurred  by re 
suspension  of  bacterial  cell  pellet  in  DEAE lysis  buffer  (20  mM  Tris-HCl,  lysozyme 
0.2mg/ml, DNaseI 10μg/ml, 1 in 1000 protease inhibitor cocktail set III pH 8) with cell 
lysis  and separation  as  above.  The soluble fraction  was then  dialysed at  least  3  times 
against 20mM Tris-HCl pH 8 in 10 kDa molecular weight cut-off dialysis  tubing. The 
soluble fraction was then applied to DEAE-sepharose pre-equilibrated with 20mM Tris-
HCl pH 8. Protein elution was achieved by increasing the concentration of NaCl. SOD1 
eluted in the low millimolar range of salt concentration. Fractions were analysed by SDS-
PAGE and  those  found  to  contain  SOD1 were  pooled,  concentrated  and  applied  to  a 
Superdex 200 16/60 gel filtration column pre-quilibriated with 20 mM Tris HCl, 150 mM 
NaCl pH 7.4 operated with an ÄKTA purifyer. The peak corresponding to dimeric SOD1 
was collected, concentrated and stored at -20 oC.
9.5 Crystallisation, soaking experiments and data collection
Crystals in the P21 space group were grown at 20  oC in sodium acetate 100 mM, NaCl 
150mM pH 4.75 using 2.5 M ammonium sulphate  as  precipitant  by the hanging drop 
vapour diffusion method from a pre-existing seed. Recombinant SOD1 crystals were also 
grown in 2.5 M ammonium sulphate, NaCl 150mM, Tri-HCl 100mM pH 8. These crystals 
formed spontaneously and were not seeded.
Appendix  IV  shows  the  compounds  used  throughout  this  study.  5-Fluorouridine, 
isoproteranol,  dopamine and adrenaline were purchased from Sigma Aldrich UK. 4-(4-
methyl-1,4-diazepan-1-yl)-2-(trifluoromethyl) quinazoline (MDTQ), 4-(4-methylpiperazin-
1-yl)quinazoline  (MPQ)  and  4-(4-methyl-1,4-diazepan-1-yl)quinazoline  (MDQ)  were 
made in house in the Department of Chemistry at the University of Liverpool through a 
collaboration with Prof. P. O'Neil and Dr N. Kershaw.
Before crystal soaking, compounds were dissolved at 50 mM in a NH4SO4 2.5 M, NaCl 
150 mM, sodium acetate  100 mM pH 4.75 solution.  Those  compounds  that  were  not 
soluble  in  this  buffer  were  dissolved  in  100% DMSO  at  a  concentration  of  50  mM. 
Crystals soaked in the former group of compounds were incubated for at least 2 hours at 20 
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oC in a drop hanging over their original  reservoir solution. Compounds in the latter group 
were mixed 1:4 with 3.3 M ammonium sulphate, NaCl 200 mM, sodium acetate 130 mM 
pH 4.75. Crystals  were then incubated in  this  solution for 2 hours at  20  oC over  their 
original  reservoir  solution.  Both  sets  of  soaked  crystals  used  paratone-N  (Molecular 
Dimensions) as cryoprotectant and were frozen in liquid nitrogen. I113T crystals grown at 
pH 8 were soaked in a similar fashion however  the compounds were dissolved in 3M 
ammonium sulphate,  150mM  NaCl,  100mM  Tris-HCl  pH  8.  A cryoprotectant  of  this 
solution with 25% glycerol was used.
X-ray crystallographic data sets were collected at Diamond Light Source station I02 and 
IO3, Oxford, UK and Soleil station Proxima 1, Saint-Aubin, France. Reflection data were 
integrated and scaled using HKL2000 113, XDS 231 or iMosflm 112 and Scala 114. Cycles of 
model building and refinement used REFMAC5 117 and COOT 232. A SOD1 model derived 
from an atomic resolution structure (PDB code: 2c9v 51) was used as the starting model.
9.6 In vitro SOD1 aggregation assay
I113T  and  L38V  SOD1  were  purified  by  DEAE  sepharose  anion  exchange 
chromatography  as  described  above.  A4V  SOD1  was  cloned  expressed  and  purified 
according to Ray et al 86. Metal ions were removed from the purified proteins according to 
the method of  McCord and Fridovich 233. After metal removal at pH 3.8, proteins were 
repeatedly dialysed  against  TBS pH 7.4 which  had previously been demetallated  with 
Chelex resin (Biorad). Compounds were dissolved in demetallated TBS pH 7.4. Protein 
and compound were mixed in  each assay in a  350  μl volume and incubated at  for 15 
minutes before addition of 5 mM EDTA whereupon they were incubated at 37oC for 4 or 
48 hours. Samples (300 μl) were analysed on a Superose-12 using an ÄKTA purifier.
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9.7 hCCS cloning and expression
The human CCS coding sequence was amplified by PCR using primers 'hCCSFwd' and 
'hCCSRev'  (Appendix  I)  from  an  EST  clone  (gi:8327523)  containing  the  full  hCCS 
sequence using KOD hotstart DNA polymerase (Novagen) according to cycling conditions:
Stage Temperature (oC) Time (s)
Initial denaturation 95 120
30 cycles
Denaturation 95 15
Annealing 55 15
Elongation 70 15
Terminal elongation 70 600
Table 9.2 PCR cycling conditions for hCCS DNA amplification.
PCR products were ligated into pCR-Zeroblunt (Appendix II) plasmid using the Zero Blunt 
PCR Cloning Kit (Invitrogen). Ligation products were transformed into Omnimax2 strain 
E. coli (Appendix III), plated onto selective solid media and incubated at 37 oC overnight. 
Transformants were cultured in selective liquid LB media overnight at 37 oC. Plasmid was 
extracted by Wizard SV Miniprep DNA Purification System (Promega) and sequenced by 
DNA  terminator  reaction  at  GATC  Biotech.  The  resulting  plasmid,  pCR-hCSS 
(AppendixII), was digested at 37  oC for one hour with NcoI and XhoI (NEB) restriction 
enzymes. The 827 bp fragment corresponding to the hCSS DNA was extracted from a 1% 
TAE agarose gel after electrophoresis at 120 V for 25 minutes in TAE buffer using Wizard 
SV Gel and PCR Clean-Up System (Promega).
Purified  hCCS  coding  DNA  was  ligated  into  NcoI-XhoI  digested  pETM11  vector 
(Appendix II) using T4 DNA ligase (NEB), transformed into Omnimax2 strain  E. coli, 
plated onto selective solid media and incubated at 37  oC overnight. Transformants were 
grown overnight at 37 oC in selective liquid LB media and plasmids extracted by Wizard 
SV Minipreps DNA Purification System. Putative pETM11-hCCS (Appendix II) plasmids 
were sequenced by GATC Biotech. pETM11-hCCS was transformed into BL21 (DE3) E. 
coli (Appendix III) and plated on selective media. Colonies were then taken and cultured in 
20 ml selective LB medium overnight at 37 oC with shaking at 220 rpm. 1 litre of selective 
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LB medium was inoculated with 10ml of this starter culture and grown at 37 oC with 220 
rpm shaking until OD600 ~ 0.5 whereupon expression was induced with IPTG at a final 
concentration of 0.4 mM. Cultures were then incubated at 30  oC with 220 rpm shaking 
overnight.
Large-scale cultures were then centrifuged at 3000 g for 20 minutes at 4  oC and the cell 
pellet separated from the culture media before freezing at -70 oC for at least 30 minutes. 
Cells were then resuspended in NiNTA lysis  buffer (NaH2PO4 50 mM, NaCl 500 mM, 
imidazole 10 mM, DTT 5mM, lysozyme 0.2mg/ml, DNaseI 10μg/ml, Protease inhibitor 
cocktail set III 1:1000 (Calbiochem), pH 7.4) and lysed by sonication on ice. Fractions 
were then separated by centrifugation at 30,000g for 2 hours at 4 oC.
9.8 Purification and tag removal
Human recombinant CCS expressed using the system described is fused to a cleavable 
hexa-histidine  tag  that  facilitates  purification  by  nickel  affinity  chromatography.  The 
soluble cell fraction generated as above was filtered through a 0.22 μm syringe filter before 
application  to  a  5  ml  NiNTA HisTrap  column  (GE  Healthcare)  pre-equilibrated  with 
NiNTA binding buffer (NaH2PO4 20 mM, NaCl 500 mM, imidazole 10 mM, DTT 5 mM, 
pH 7.4). After application, the column was washed with ten column volumes of NiNTA 
binding  buffer.  The  protein  was  then  eluted  by application  of  ten  column volumes  of 
NiNTA elution  buffer  (NaH2PO4 20  mM,  NaCl  500  mM,  DTT 5  mM,  pH  7.4)  with 
gradually increasing imidazole concentration (10 mM – 500 mM).
The semi-pure protein was then dialysed against NiNTA binding buffer and TEV (Tobacco 
Etch  Virus)  protease  subsequently  added  to  a  final  concentration  of  100  μg/ml  and 
incubated at  4  oC overnight. This solution was then reapplied to a NiNTA column and 
recombinant hCCS protein was collected as the flow through. The pure protein was then 
dialysed against  storage buffer  (Tris-HCl 50 mM, NaCl 150mM, DTT 5mM,  pH 8.0) 
concentrated and applied to either a Superdex 200 10/30 or Superdex 200 16/60 column. 
Fractions were analysed by SDS-PAGE and those containing the 29.1 kDa protein were 
pooled and stored at 4 oC or frozen at -20 oC.
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9.9 hCCS-SOD1 heterodimeric complex formation
hCCS-SOD1 complex formation was carried out  roughly according to the protocols of 
Winkler et al 208 and Lamb et al 215. SOD1 and its fALS associated mutants were expressed 
and purified according to the method described in the previous sections. Before mixing 
SOD1 and hCCS,  5  mM DTT was  added to the  SOD1 buffer  and incubated  at  room 
temperature for at least 4hours. Protein were mixed in a 1:1.5 hCCS:SOD1 molar ratio. 
After mixing, the proteins were loaded on a Superdex 200 16/60 column pre-equilibriated 
with Tris-HCl 50 mM, NaCl 150 mM DTT 5 mM. Protein elution was monitored by UV 
absorption at 280 nm and 260 nm.
9.10 Small-angle X-ray data collection and processing
SAXS data for homodimeric hCCS were collected on the SWING beamline at SOLEIL 
synchrotron, St Aubin, France, using the HPLC integrated SAXS setup 211. Protein (400 μg 
in 40 μl storage buffer) was loaded onto a pre-equilibrated Shodex KW402.5-4F 150 kDa 
SEC column at a flow rate of 80 μl/min using an Agilent 1200 series HPLC at 25 oC before 
passing through the beam  with wavelength 1.03 Å. The sample to detector distance was 
set to 180 cm. 250 exposures of 2 seconds duration were taken over the course of protein 
elution  with 1 second dead time between each.  20 frames  were taken prior  to  protein 
elution for buffer subtraction purposes.
SAXS data for the heterodimeric hCCS-SOD1 complex were acquired in a similar fashion 
however  a  Superdex  200  16/60  column  was  used  for  protein  separation.  Column 
temperature was kept at 20 oC using a chilled water bath and a flow rate of 0.75 ml/min 
was established. 250 frames were taken over the course of protein elution with a 3 second 
exposure  time  separated  by 1.5 seconds  dead time.  100 frames  were taken before  the 
protein eluted for buffer subtraction. Samples of differing concentrations were loaded in a 
900 μl volume.
Scattering intensity was recorded on an AVIEX170x170 mm CCD detector over an angular 
range qmin = 0.01 Å-1 to qmax = 0.5 Å-1. Data averaging and reduction, including preliminary 
Rg and I(0) calculations, were carried out using the Foxtrot suite developed at SOLEIL for 
the SWING beamline. Further analysis was performed with PRIMUS 234 where radius of 
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gyration  values  were  determined  fulfilling  the  condition  qR(g)<1.3.  Particle  distance 
distribution function p(r) analysis was carried out using iterative cycles of GNOM 235 using 
the Guinier R(g) values as guide for refinement of Dmax. Ab initio 3-D shape reconstruction 
was then performed, without the imposition of symmetry restraints for hCCS and hCCS-
SOD1 and with an enforced two-fold symmetry axis for SOD1, using the GASBOR web 
server  (EMBL Hamburg)  203.  20  models  were  averaged  with  DAMAVER  236 and  the 
resulting structures compared in PyMOL 237.
9.11 Rigid body modelling
The published crystal structure of hCCS domain II  195 was used as a the structural model 
for the hCCS amino acid region 88 – 232 (PDB ID: 1DO5). The structure of region 12 – 69 
was  inferred  from the  NMR model  of  this  domain (PDB ID:  2CRL).  The  secondary 
structure of the short α-helix found in domain III, amino acids 250 – 258, was inferred 
using I-TASSER  238. Terminal and linker regions 1 – 11 (with the addition of two extra 
amino acids remaining from TEV cleavage of the hexa-histidine tag), 77 – 87, 233 – 249 
and 259 – 274 are predicted to be unstructured.
The  hCCS homodimer  was  modelled  using  BUNCH  204 to  generate  25  hCCS models 
constrained by the position of the SOD1-like domain II that forms the interface between 
two CCS monomers. The hCCS-SOD1 heterodimer was modelled using CORAL, a variant 
of  BUNCH  that  facilitates  analysis  of  protein  complexes.  In  both  cases,  unrestrained 
movement  of  hCCS  domain  I  and  III  together  with  the  flexible  linker  regions  was 
permitted. BUNCH and CORAL only generate Cα-atom positions for flexible structural 
segments such as linkers and peptide terminal ends. For the purposes of visualisation the 
protein backbone and sidechain positions of these flexible regions were reconstructed from 
their  Cα traces  using  the  SABBAC  web  server  239.  The  scattering  profile  of  each 
reconstructed and complete model was then computed with CRYSOL 240.
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Appendices 
Appendix I – Summary of Oligonucleotides
Name Restriction Site Sequence
SOD1Fwd XbaI 5'-TCTAGAATGGCGACGAAGGCC-3'
SOD1Rev XhoI 5'-CTCGAGTCAAAGGTGGGCAGGGGGC-3'
L38V N/A 5'-TGTGGGGAAGCATTAAAGGAGTGACTGAAGGCCT-3'
L38V-AS N/A 5'-AGGCCTTCAGTCACTCCTTTAATGCTTCCCCACA-3'
I113T N/A 5'-TCTCAGGAGACCATTGCATCACTGGCCGCACAC-3'
I113T-AS N/A 5'-GTGTGCGGCCAGTGATGCAATGGTCTCCTGAGA-3'
A4V N/A 5'-CCGCGACGAAGGTCGTGTGCGTGCT-3'
A4V-AS N/A 5'-AGCACGCACACGACCTTCGTCGCGG-3'
hCCSFwd NcoI 5'-CCATGGCTTCGGATTCGGGGAAC-3'
hCCSRev XhoI 5'-CTCGAGTCAAAGGTGGGCAGGGGGC-3'
Appendix II – Summary of Plasmids
Name Source Insert Size (bp)  Resistance
pCR-Blunt Invitrogen N/A 3512 Kanamycin
pCR-hSOD1wt N/A Human wild-type SOD1 3985 Kanamycin
pETM-11 EMBL N/A 5400 Kanamycin
pGEX6P1 GE Healthcare N/A 4984 Ampicillin
pET303 Invitrogen N/A 5369 Ampicillin
pET303-hSOD1wt N/A Human wild-type SOD1 5828 Ampicillin
pET303-hSOD1 L38V N/A hSOD1 with L38V mutation 5828 Ampicillin
pET303-hSOD1 I113T N/A hSOD1 with I113T mutation 5828 Ampicillin
pETM11-hCCS N/A Human wild-type CCS 6137 Kanamycin
pGEX6-hSOD1 A4V N/A hSOD1 with A4V mutation 5428 Ampicillin
Appendix III – E. coli Strains
Name Supplier Genotype
Omnimax 2 Invitrogen F {proAB+ lacIq lacZΔM15 Tn10(TetR) Δ(ccdAB)} mcrA Δ(mrr-hsdRMS-
mcrBC) φ80(lacZ)ΔM15 Δ(lacZYA-argF) U169 endA1 recA1 supE44 thi-1 
gyrA96 relA1 tonA panD
BL21 (DE3) Novagen F– ompT hsdSB(rB- mB-) dcm gal λ(DE3) 
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Appendix IV – Compounds
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